OnCo Edge

Approval: FDA approves talazoparib with enzalutamide for metastatic androgen pathway modulation-naïve or -sensitive prostate cancer with HRR gene mutations

2026-10-26T00:00:00Z

On October 26, 2026, the Food and Drug Administration (FDA) approved talazoparib (Talzenna, Pfizer Inc.) in combination with enzalutamide for the treatment of adults with metastatic androgen pathway modulation-naïve or -sensitive (mAPMN/S) prostate cancer with homologous recombination repair (HRR) gene mutations, as detected by an FDA-authorized test.

26 October 2026, FDA.

On OnCo: Enzalutamide, Talazoparib, Prostate cancer

Approval: FDA grants accelerated approval to dostarlimab for locally advanced rectal cancer

2026-10-19T00:00:00Z

On October 19, 2026, the Food and Drug Administration granted accelerated approval to dostarlimab (Jemperli, GSK) for adults with Stage II/III locally advanced rectal cancer (LARC) that is microsatellite instability high (MSI-H) or mismatch repair deficient (dMMR), as determined by an FDA-authorized test for solid tumors.

19 October 2026, FDA.

On OnCo: Dostarlimab, Rectal cancer, Colorectal cancer

Paper: Clinical Complete Response with Dostarlimab Monotherapy in dMMR/MSI-H Locally Advanced Rectal Cancer: First Results from the Global AZUR-1 Trial.

2026-10-25T00:00:00Z

Published in Ann Oncol on 25 October 2026; found by the roadmap watch for AZUR-1.

25 October 2026, Ann Oncol.

On OnCo: AZUR-1, Colorectal cancer roadmap: from the adenoma-carcinoma sequence and the first screening trials to total mesorectal excision, oxaliplatin, RAS testing, immunotherapy for mismatch repair-deficient disease, ctDNA-guided treatment and organ preservation, Surgery roadmap: radical operations → less surgery → no surgery when a drug has done the work

Proposal: Proposed approval: Aspirin

2026-10-31T00:00:00Z

openFDA has a label for "Aspirin".

31 October 2026, FDA.

On OnCo: Aspirin, Danazol, Givinostat, Ivermectin, Metyrapone, Mifepristone, Pancrelipase

Proposal: Proposed new product: Casgevy

2026-10-31T00:00:00Z

EMA register: Casgevy (exagamglogene autotemcel) Authorised, 2024-02-09.

31 October 2026, EMA.

Proposal: Proposed new product: Cystagon

2026-10-31T00:00:00Z

EMA register: Cystagon (mercaptamine bitartrate) Authorised, 1997-06-23.

31 October 2026, EMA.

Proposal: Proposed new product: Entyvio

2026-10-31T00:00:00Z

EMA register: Entyvio (vedolizumab) Authorised, 2014-05-22.

31 October 2026, EMA.

Proposal: Proposed new product: Libmeldy

2026-10-31T00:00:00Z

EMA register: Libmeldy (autologous CD34+ cells encoding ARSA gene) Authorised, 2020-12-17.

31 October 2026, EMA.

Proposal: Proposed new product: Lumeblue

2026-10-31T00:00:00Z

EMA register: Lumeblue (previously Methylthioninium chloride Cosmo) (methylthioninium chloride) Authorised, 2020-08-19.

31 October 2026, EMA.

Proposal: Proposed new product: Lynkuet

2026-10-31T00:00:00Z

EMA register: Lynkuet (elinzanetant) Authorised, 2025-11-17.

31 October 2026, EMA.

Proposal: Proposed new product: NeoRecormon

2026-10-31T00:00:00Z

EMA register: NeoRecormon (epoetin beta) Authorised, 1997-07-16.

31 October 2026, EMA.

Proposal: Proposed new product: Nezglyal

2026-10-31T00:00:00Z

EMA register: Nezglyal (leriglitazone) Authorised, 2026-09-21.

31 October 2026, EMA.

Proposal: Proposed new product: Procysbi

2026-10-31T00:00:00Z

EMA register: Procysbi (mercaptamine) Authorised, 2013-09-05.

31 October 2026, EMA.

Proposal: Proposed new product: SomaKit TOC

2026-10-31T00:00:00Z

EMA register: SomaKit TOC (edotreotide) Authorised, 2016-12-08.

31 October 2026, EMA.

Proposal: Proposed new product: Strimvelis

2026-10-31T00:00:00Z

EMA register: Strimvelis (autologous CD34+ enriched cell fraction that contains CD34+ cells transduced with retroviral vector that encodes for the human ADA cDNA sequence) Authorised, 2016-05-26.

31 October 2026, EMA.

Proposal: Proposed new product: Waskyra

2026-10-31T00:00:00Z

EMA register: Waskyra (etuvetidigene autotemcel) Authorised, 2026-01-09.

31 October 2026, EMA.

Proposal: Proposed new product: Xromi

2026-10-31T00:00:00Z

EMA register: Xromi (hydroxycarbamide) Authorised, 2019-07-01.

31 October 2026, EMA.

Proposal: Proposed new product: Yartemlea

2026-10-31T00:00:00Z

EMA register: Yartemlea (Narsoplimab) Opinion.

31 October 2026, EMA.

Proposal: Proposed new product: Zefylti

2026-10-31T00:00:00Z

EMA register: Zefylti (filgrastim) Application withdrawn.

31 October 2026, EMA.

Proposal: Proposed regional approval row: Daraxonrasib

2026-10-31T00:00:00Z

EMA register: Rasonque (Daraxonrasib) Opinion.

31 October 2026, EMA.

On OnCo: Daraxonrasib

Proposal: Proposed trial status change: A Phase II Clinical Trial of DZD9008 in Combination With AZD4205 in Standard Treatment Failed NSCLC Patients With EGFR Mutations

2026-10-31T00:00:00Z

ClinicalTrials.gov overall status is COMPLETED; recorded recruiting.

31 October 2026, ClinicalTrials.gov.

On OnCo: A Phase II Clinical Trial of DZD9008 in Combination With AZD4205 in Standard Treatment Failed NSCLC Patients With EGFR Mutations

Proposal: Proposed trial status change: A Study of Trastuzumab Deruxtecan in People With Non-Small Cell Lung Cancer

2026-10-31T00:00:00Z

ClinicalTrials.gov overall status is WITHDRAWN; recorded recruiting.

31 October 2026, ClinicalTrials.gov.

On OnCo: A Study of Trastuzumab Deruxtecan in People With Non-Small Cell Lung Cancer

Proposal: Proposed trial status change: A Study to Evaluate INCB099280 in Participants With Select Solid Tumors Who Are Immune Checkpoint Inhibitor Naive

2026-10-31T00:00:00Z

ClinicalTrials.gov overall status is TERMINATED; recorded active.

31 October 2026, ClinicalTrials.gov.

On OnCo: A Study to Evaluate INCB099280 in Participants With Select Solid Tumors Who Are Immune Checkpoint Inhibitor Naive

Paper: Adjuvant chemotherapy with cisplatin and gemcitabine compared to standard of care after curative intent resection of cholangiocarcinoma and muscle invasive gallbladder carcinoma (ACTICCA-1/AIO-HEP-0112 trial).

2026-10-24T00:00:00Z

Published in Ann Oncol on 24 October 2026; found by the roadmap watch for ACTICCA-1.

24 October 2026, Ann Oncol.

On OnCo: ACTICCA-1, Gallbladder cancer roadmap: from a chance finding at gallstone surgery to a disease with its own trials

Paper: Atirmociclib and fulvestrant for patients with HR+/HER2- advanced/metastatic breast cancer who progressed on a prior cyclin-dependent kinase 4/6 inhibitor: primary analysis of the randomized FourLight-1 trial.

2026-10-24T00:00:00Z

Published in Ann Oncol on 24 October 2026; found by the roadmap watch for FOURLIGHT-1.

24 October 2026, Ann Oncol.

On OnCo: FOURLIGHT-1, Hormonal therapy roadmap: removing the ovaries → tamoxifen → oral degraders switched by a blood test

Paper: Final results of nivolumab plus ipilimumab versus nivolumab or chemotherapy in microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer from CheckMate 8HW.

2026-10-24T00:00:00Z

Published in Ann Oncol on 24 October 2026; found by the roadmap watch for CheckMate 8HW.

24 October 2026, Ann Oncol.

On OnCo: CheckMate 8HW, Colorectal cancer roadmap: from the adenoma-carcinoma sequence and the first screening trials to total mesorectal excision, oxaliplatin, RAS testing, immunotherapy for mismatch repair-deficient disease, ctDNA-guided treatment and organ preservation

Paper: Overall survival from the phase III postMONARCH trial of abemaciclib plus fulvestrant versus placebo plus fulvestrant for HR+, HER2- advanced breast cancer following progression on a prior CDK4/6 inhibitor plus endocrine therapy.

2026-10-24T00:00:00Z

Published in Ann Oncol on 24 October 2026; found by the roadmap watch for postMONARCH.

24 October 2026, Ann Oncol.

On OnCo: postMONARCH, Hormonal therapy roadmap: removing the ovaries → tamoxifen → oral degraders switched by a blood test

Issue: OnCo weekly, 2026-10-30

2026-10-30T00:00:00Z

1105 changelog entries, 5 corrections.

30 October 2026, OnCo weekly issue.

Paper: Active surveillance versus standard surgery after neoadjuvant chemoradiotherapy for oesophageal cancer: long-term results of a cluster-randomised controlled trial (SANO).

2026-10-23T00:00:00Z

Published in Ann Oncol on 23 October 2026; found by the roadmap watch for SANO.

23 October 2026, Ann Oncol.

On OnCo: SANO, Surgery roadmap: radical operations → less surgery → no surgery when a drug has done the work

Paper: Capivasertib plus abiraterone in PTEN-deficient de novo metastatic hormone-sensitive prostate cancer: updated survival analysis from CAPItello-281.

2026-10-23T00:00:00Z

Published in Ann Oncol on 23 October 2026; found by the roadmap watch for CAPItello-281.

23 October 2026, Ann Oncol.

On OnCo: CAPItello-281, Hormonal therapy roadmap: removing the ovaries → tamoxifen → oral degraders switched by a blood test, Prostate cancer roadmap: from Huggins and the discovery that a cancer can depend on a hormone, through the PSA epidemic and what it cost, the androgen receptor drugs, the DNA repair subset and PSMA, to a 2032 registry watch

Paper: Lymph node-targeted, mKRAS-specific amphiphile vaccine in pancreatic cancer: the randomized phase 2 AMPLIFY-7P trial.

2026-10-23T00:00:00Z

Published in Nat Med on 23 October 2026; found by the roadmap watch for AMPLIFY-7P.

23 October 2026, Nat Med.

On OnCo: AMPLIFY-7P, Pancreatic cancer roadmap: from Whipple's operation to gemcitabine, FOLFIRINOX, adjuvant chemotherapy, PARP inhibition, KRAS inhibition, vaccines and the surveillance question

Paper: Overall survival with adjuvant ribociclib plus nonsteroidal aromatase inhibitor in patients with high-risk HR+/HER2- early breast cancer: Six-year follow-up of the NATALEE trial.

2026-10-23T00:00:00Z

Published in Ann Oncol on 23 October 2026; found by the roadmap watch for NATALEE.

23 October 2026, Ann Oncol.

On OnCo: NATALEE, Hormonal therapy roadmap: removing the ovaries → tamoxifen → oral degraders switched by a blood test

Approval: FDA grants traditional approval for pembrolizumab or pembrolizumab and berahyaluronidase alfa-pmph for unresectable or metastatic TMB-H solid tumors with updated indication

2026-10-16T00:00:00Z

On October 16, 2026, the Food and Drug Administration granted traditional approval to pembrolizumab (Keytruda, Merck) or pembrolizumab and berahyaluronidase alfa-pmph (Keytruda Qlex, Merck) for adult and pediatric patients with unresectable or metastatic tumor mutational burden-high (TMB-H) [≥13 mutations/megabase (mut/Mb)] solid tumors, as determined by an FDA-authorized test, that have progressed following prior treatment and who have no satisfactory alternative treatment options.

16 October 2026, FDA.

On OnCo: Pembrolizumab

Issue: OnCo weekly, 2026-10-29

2026-10-29T00:00:00Z

1100 changelog entries, 5 corrections.

29 October 2026, OnCo weekly issue.

Paper: Deep phenotyping of blood cell data reveals novel clinical biomarkers.

2026-10-28T00:00:00Z

Published on 28 October 2026 after first appearing as a preprint; matched Single-cell & spatial profiling.

28 October 2026.

On OnCo: Single-cell & spatial profiling

Paper: Disease-free survival and overall survival after neoadjuvant immunotherapy in mismatch repair-deficient colon cancer in the Netherlands: results of the single-arm, multicentre, phase 2, NICHE-2 trial.

2026-10-21T00:00:00Z

Published in Lancet on 21 October 2026; found by the roadmap watch for NICHE-2.

21 October 2026, Lancet.

On OnCo: NICHE-2, Colorectal cancer roadmap: from the adenoma-carcinoma sequence and the first screening trials to total mesorectal excision, oxaliplatin, RAS testing, immunotherapy for mismatch repair-deficient disease, ctDNA-guided treatment and organ preservation, Surgery roadmap: radical operations → less surgery → no surgery when a drug has done the work, Trial modernisation roadmap: the randomised trial → platforms and adaptive designs → decentralised, pragmatic and always-on

Approval: FDA approves an expanded indication for nogapendekin alfa inbakicept-pmln for BCG-unresponsive non-muscle invasive bladder cancer

2026-10-14T00:00:00Z

On October 14, 2026, the Food and Drug Administration (FDA) approved nogapendekin alfa inbakicept-pmln (Anktiva, Altor BioScience, LLC, an indirect wholly-owned subsidiary of ImmunityBio, Inc.) with Bacillus Calmette-Guérin (BCG) for adults with BCG-unresponsive non-muscle invasive bladder cancer (NMIBC).

14 October 2026, FDA.

On OnCo: Nogapendekin alfa inbakicept, Bladder & urothelial cancer, Non-muscle-invasive bladder cancer

Issue: OnCo weekly, 2026-10-27

2026-10-27T00:00:00Z

1068 changelog entries, 3 corrections.

27 October 2026, OnCo weekly issue.

Paper: Activity-based proteomics discovery of deubiquitinating enzyme inhibitors with immunomodulatory activity.

2026-10-26T00:00:00Z

Published on 26 October 2026 after first appearing as a preprint; matched Proteomics & phosphoproteomics.

26 October 2026.

On OnCo: Proteomics & phosphoproteomics

Paper: Colorectal cancers with distinct metastatic potential trigger divergent early T cell responses.

2026-10-26T00:00:00Z

Published on 26 October 2026 after first appearing as a preprint; matched MET, State and CIITA.

26 October 2026.

On OnCo: MET, State, CIITA, CD4

Paper: Comparative characterization of OncoPro™ and Wnt-based media reveals distinct phenotypic and pharmacologic states in patient-derived tumor organoids.

2026-10-26T00:00:00Z

Published on 26 October 2026 after first appearing as a preprint; matched Whole-exome & whole-genome sequencing, RNA sequencing & expression profiling and Single-cell & spatial profiling.

26 October 2026.

On OnCo: Whole-exome & whole-genome sequencing, RNA sequencing & expression profiling, Single-cell & spatial profiling, State, LGR5

Paper: Design of Tissue-Selective PROTACs Through Recruiting E3 Ligase Scaffolding Protein MAGEA11.

2026-10-26T00:00:00Z

Published on 26 October 2026 after first appearing as a preprint; matched PROTACs & molecular glues, Proteasome and Cereblon.

26 October 2026.

On OnCo: PROTACs & molecular glues, Proteasome, Cereblon, BRD4, VHL, MAX

Paper: E2 displacement of CIP2A from TOPBP1 activates the DNA damage response during papillomavirus life cycles.

2026-10-26T00:00:00Z

Published on 26 October 2026 after first appearing as a preprint; matched ATR, ATM and CIP2A.

26 October 2026.

On OnCo: ATR, ATM, CIP2A, SIRT1

Paper: Iberdomide (Zenbexus) for multiple myeloma.

2026-10-26T00:00:00Z

Published in Med Lett Drugs Ther on 26 October 2026; matched the OnCo record for Iberdomide.

26 October 2026, Med Lett Drugs Ther.

On OnCo: Iberdomide

Paper: Mid-zone hepatocytes trade proliferation for survival via Atf4-Chop axis in early acute liver injury.

2026-10-26T00:00:00Z

Published on 26 October 2026 after first appearing as a preprint; matched Single-cell & spatial profiling, Spatial transcriptomics and BTG2.

26 October 2026.

On OnCo: Single-cell & spatial profiling, Spatial transcriptomics, BTG2

Paper: Navigating HPV vaccination challenges in low-resource settings: Practical strategies for estimating the size of out-of-school girls.

2026-10-26T00:00:00Z

Published on 26 October 2026 after first appearing as a preprint; matched HPV & HBV vaccination.

26 October 2026.

On OnCo: HPV & HBV vaccination

Issue: OnCo weekly, 2026-10-26

2026-10-26T00:00:00Z

1065 changelog entries, 3 corrections.

26 October 2026, OnCo weekly issue.

Paper: RAStoERK: A reference interaction atlas for insights into signaling and disease.

2026-10-26T00:00:00Z

Published on 26 October 2026 after first appearing as a preprint; matched Atlas and ARAF.

26 October 2026.

On OnCo: Atlas, ARAF

Paper: Reversibility of nuclear and 3D genomic changes in non-cancerous fibroblasts after constricted migration.

2026-10-26T00:00:00Z

Published on 26 October 2026 after first appearing as a preprint; matched State.

26 October 2026.

On OnCo: State

Paper: SARS-CoV-2 main protease inhibition through dimerization promotion by peptidomimetic inhibitors and disruption by ebselen.

2026-10-26T00:00:00Z

Published on 26 October 2026 after first appearing as a preprint; matched State.

26 October 2026.

On OnCo: State

Paper: The 9-1-1 complex protects ssDNA gaps in BRCA2-deficient cancer.

2026-10-26T00:00:00Z

Published on 26 October 2026 after first appearing as a preprint; matched CRISPR functional genomics, ATR and BRCA1 / BRCA2.

26 October 2026.

On OnCo: CRISPR functional genomics, ATR, BRCA1 / BRCA2, ERCC4, EXO1

Paper: The transcription factor BCL11A restores differentiation potential to aged oligodendrocyte progenitor cells.

2026-10-26T00:00:00Z

Published on 26 October 2026 after first appearing as a preprint; matched BCL11A.

26 October 2026.

On OnCo: BCL11A

Paper: The yEvo Mutation Browser: Enhancing student understanding of experimental evolution and genomics through interactive data visualization.

2026-10-26T00:00:00Z

Published on 26 October 2026 after first appearing as a preprint; matched Whole-exome & whole-genome sequencing.

26 October 2026.

On OnCo: Whole-exome & whole-genome sequencing

Paper: xNNPCD identifies regulators of programmed cell death by integrating perturbation transcriptomes with cancer dependency profiles.

2026-10-26T00:00:00Z

Published on 26 October 2026 after first appearing as a preprint; matched Decitabine, SLC6A2 and HSPA5.

26 October 2026.

On OnCo: Decitabine, SLC6A2, HSPA5

Paper: Chemical shift assignments of the dimerization domain of NF-KappaB c-Rel subunit.

2026-10-25T00:00:00Z

Published on 25 October 2026 after first appearing as a preprint; matched REL, RELA and CD40.

25 October 2026.

On OnCo: REL, RELA, CD40

Paper: Fusion Detection in Microsecretory Adenocarcinoma and Mucoepidermoid Carcinoma Using Chromogenic RNA In Situ Hybridization: A Promising Alternative to DNA-Based Fluorescence In-Situ Hybridization.

2026-10-25T00:00:00Z

Published on 25 October 2026 after first appearing as a preprint; matched MEF2C, MAML2 and CRTC1.

25 October 2026.

On OnCo: MEF2C, MAML2, CRTC1, SS18

Paper: EZH2 coordinates inflammatory and pain-associated pathways across joint compartments in osteoarthritis.

2026-10-24T00:00:00Z

Published on 24 October 2026 after first appearing as a preprint; matched Proteomics & phosphoproteomics, Epigenetic drugs and EZH2.

24 October 2026.

On OnCo: Proteomics & phosphoproteomics, Epigenetic drugs, EZH2, Mia, PAX6

Paper: HHV8-associated multicentric Castleman disease with Kaposi sarcoma in an immunocompetent patient: a case report and review of the literature.

2026-10-24T00:00:00Z

Published on 24 October 2026 after first appearing as a preprint; matched KMT2A (MLL) rearrangement, Rituximab and Doxorubicin.

24 October 2026.

On OnCo: KMT2A (MLL) rearrangement, Rituximab, Doxorubicin, EML4, ATRX, KLF4

Paper: High prevalence of TROP2 expression identifies EBV-positive gastric cancer as a candidate for TROP2-directed antibody-drug conjugates.

2026-10-24T00:00:00Z

Published on 24 October 2026 after first appearing as a preprint; matched Histopathology & immunohistochemistry, Antibody-drug conjugate and Immune checkpoint inhibitors.

24 October 2026.

On OnCo: Histopathology & immunohistochemistry, Antibody-drug conjugate, Immune checkpoint inhibitors, TROP2

Paper: Human T cells from resistant hypertension patients promote hypertension via tnf in humanized mice.

2026-10-24T00:00:00Z

Published on 24 October 2026 after first appearing as a preprint; matched CLTC and CD4.

24 October 2026.

On OnCo: CLTC, CD4

Paper: Interferon Regulatory Factor 8 Drives Autoimmune Neuroinflammation in Experimental Autoimmune Encephalomyelitis.

2026-10-24T00:00:00Z

Published on 24 October 2026 after first appearing as a preprint; matched IRF8.

24 October 2026.

On OnCo: IRF8

Paper: Modelling the potential contributions of polygenic risk stratification to cost-effective screening for prostate cancer.

2026-10-24T00:00:00Z

Published on 24 October 2026 after first appearing as a preprint; matched KLK3.

24 October 2026.

On OnCo: KLK3

Paper: Post-embolization dynamic changes in Obsidio Conformable Embolic: volume and radiodensity analysis.

2026-10-24T00:00:00Z

Published on 24 October 2026 after first appearing as a preprint; matched CT.

24 October 2026.

On OnCo: CT

Paper: SLC16A13 Promotes Malignant Progression in Glioma via Metabolic Reprogramming and Disruption of Monocarboxylate Homeostasis.

2026-10-24T00:00:00Z

Published on 24 October 2026 after first appearing as a preprint; matched Pertuzumab, Atlas and Ki-67.

24 October 2026.

On OnCo: Pertuzumab, Atlas, Ki-67, TERT

Paper: Can mesenchymal stem cell and retinoic acid therapies more effectively reduce lung damage due to bronchopulmonary dysplasia?

2026-10-23T00:00:00Z

Published on 23 October 2026 after first appearing as a preprint; matched Mesenchymal stromal cells for tissue damage.

23 October 2026.

On OnCo: Mesenchymal stromal cells for tissue damage

Paper: Cell-state-specific metabolic networks govern ferroptosis versus apoptosis in small cell lung cancer.

2026-10-23T00:00:00Z

Published on 23 October 2026 after first appearing as a preprint; matched State and ASCL1.

23 October 2026.

On OnCo: State, ASCL1

Paper: Differential roles for the spindle assembly checkpoint in error surveillance and mitotic timing.

2026-10-23T00:00:00Z

Published on 23 October 2026 after first appearing as a preprint; matched Synthetic lethality approaches, APC and MXI1.

23 October 2026.

On OnCo: Synthetic lethality approaches, APC, MXI1

Paper: FITdb, an integrated Functional Immunogenomics and Transcriptomics database.

2026-10-23T00:00:00Z

Published on 23 October 2026 after first appearing as a preprint; matched Single-cell & spatial profiling.

23 October 2026.

On OnCo: Single-cell & spatial profiling

Paper: LRP2: A proteogenomics pipeline for long-read informed protein isoform analysis and discovery.

2026-10-23T00:00:00Z

Published on 23 October 2026 after first appearing as a preprint; matched RNA sequencing & expression profiling.

23 October 2026.

On OnCo: RNA sequencing & expression profiling

Paper: Midzone bundles of the mammalian anaphase spindle are mechanically coupled both locally and globally.

2026-10-23T00:00:00Z

Published on 23 October 2026 after first appearing as a preprint; matched PRC1.

23 October 2026.

On OnCo: PRC1

Paper: PARP1 directly disassembles nucleosomes to regulate DNA repair.

2026-10-23T00:00:00Z

Published on 23 October 2026 after first appearing as a preprint; matched PARP.

23 October 2026.

On OnCo: PARP

Paper: RAF isoform selectivity of MEK inhibitors and rational design of a covalent ARAF-MEK inhibitor.

2026-10-23T00:00:00Z

Published on 23 October 2026 after first appearing as a preprint; matched CRAF, Trametinib and ARAF.

23 October 2026.

On OnCo: CRAF, Trametinib, ARAF

Paper: Retroviral insertions contributed to the divergence of human and chimpanzee brains.

2026-10-23T00:00:00Z

Published on 23 October 2026 after first appearing as a preprint; matched DNA methylation profiling.

23 October 2026.

On OnCo: DNA methylation profiling

Paper: Serine auxotrophy is a targetable vulnerability driven by PSAT1 suppression in AML.

2026-10-23T00:00:00Z

Published on 23 October 2026 after first appearing as a preprint; matched Venetoclax and MECOM.

23 October 2026.

On OnCo: Venetoclax, MECOM

Paper: Short-term outcomes of mini-thoracotomy, multiportal video-assisted thoracic surgery, and multiportal robot-assisted thoracic surgery for complex segmentectomy.

2026-10-23T00:00:00Z

Published on 23 October 2026 after first appearing as a preprint; matched Azacitidine and Decitabine + cedazuridine.

23 October 2026.

On OnCo: Azacitidine, Decitabine + cedazuridine

Paper: Structural basis for start codon selection by eIF5-mimic proteins.

2026-10-23T00:00:00Z

Published on 23 October 2026 after first appearing as a preprint; matched MYC.

23 October 2026.

On OnCo: MYC

Paper: TET2-driven activation of AGO2 links epigenetic remodeling to myeloid commitment and leukemia.

2026-10-23T00:00:00Z

Published on 23 October 2026 after first appearing as a preprint; matched DNA methylation profiling and TET2.

23 October 2026.

On OnCo: DNA methylation profiling, TET2

Paper: Efficacy and safety of camrelizumab plus docetaxel and carboplatin as neoadjuvant therapy for stage II-III triple-negative breast cancer: the HELEN-Trio 011 randomized clinical trial.

2026-10-16T00:00:00Z

Published in Ann Oncol on 16 October 2026; matched the OnCo record for Camrelizumab.

16 October 2026, Ann Oncol.

On OnCo: Camrelizumab

Paper: Genomic and clinical landscape of RAS mutations in acute myeloid leukemia.

2026-10-16T00:00:00Z

Published in Blood on 16 October 2026; matched the OnCo record for CBL.

16 October 2026, Blood.

On OnCo: CBL, GNA13

Paper: Evaluating disparities in counseling and resources for chemotherapy-induced hair loss: qualitative analysis of a survey-based approach.

2026-10-22T00:00:00Z

Published on 22 October 2026 after first appearing as a preprint; matched Scalp cooling.

22 October 2026.

On OnCo: Scalp cooling

Paper: Hypoxia-induced GP73 promotes the Warburg effect in hepatocellular carcinoma via HIF-1α.

2026-10-22T00:00:00Z

Published on 22 October 2026 after first appearing as a preprint; matched Transarterial chemoembolisation, Oligonucleotide therapeutics and HIF-1α.

22 October 2026.

On OnCo: Transarterial chemoembolisation, Oligonucleotide therapeutics, HIF-1α

Paper: MCT6 is an intestinal Lac-Phe exporter required for metformin-associated weight loss.

2026-10-22T00:00:00Z

Published on 22 October 2026 after first appearing as a preprint; matched State and Metformin as an anti-ageing drug after cancer.

22 October 2026.

On OnCo: State, Metformin as an anti-ageing drug after cancer

Paper: No-known-vector flaviviruses exhibit diverse replication and virulence phenotypes in mice.

2026-10-22T00:00:00Z

Published on 22 October 2026 after first appearing as a preprint; matched Interferon alpha receptor and IFNGR1.

22 October 2026.

On OnCo: Interferon alpha receptor, IFNGR1

Issue: OnCo weekly, 2026-10-22

2026-10-22T00:00:00Z

1043 changelog entries, 1 upcoming date, 1 correction.

22 October 2026, OnCo weekly issue.

Paper: OpenDVP: an experimental and computational framework for community-empowered deep visual proteomics.

2026-10-22T00:00:00Z

Published on 22 October 2026 after first appearing as a preprint; matched Single-cell & spatial profiling, Proteomics & phosphoproteomics and Nicheformer.

22 October 2026.

On OnCo: Single-cell & spatial profiling, Proteomics & phosphoproteomics, Nicheformer, State

Paper: Pathogenic Keratinocyte States and Fibroblast Niches Define the Tissue Microenvironment in Severe Hidradenitis Suppurativa.

2026-10-22T00:00:00Z

Published on 22 October 2026 after first appearing as a preprint; matched RNA sequencing & expression profiling, Single-cell & spatial profiling and Spatial transcriptomics.

22 October 2026.

On OnCo: RNA sequencing & expression profiling, Single-cell & spatial profiling, Spatial transcriptomics, State

Paper: Protective role of Galectin-3 in prion disease through regulation of microglial PrPSc uptake.

2026-10-22T00:00:00Z

Published on 22 October 2026 after first appearing as a preprint; matched NR4A3.

22 October 2026.

On OnCo: NR4A3

Paper: Quantifying dexterity and grip strength associations between age, cognitive function (MoCA), and cerebellar gray matter volume in healthy adults across the adult lifespan.

2026-10-22T00:00:00Z

Published on 22 October 2026 after first appearing as a preprint; matched Atlas.

22 October 2026.

On OnCo: Atlas

Paper: Toll-like receptor expression across histological states of epidermodysplasia verruciformis.

2026-10-22T00:00:00Z

Published on 22 October 2026 after first appearing as a preprint; matched LATS1.

22 October 2026.

On OnCo: LATS1

Paper: XIST drives X-chromosome inactivation and safeguards female extraembryonic cells in humans.

2026-10-22T00:00:00Z

Published on 22 October 2026 after first appearing as a preprint; matched DNA methylation profiling and State.

22 October 2026.

On OnCo: DNA methylation profiling, State

Paper: Additional Analyses to Address Model Used to Adjust for Crossover in the ClarIDHy Trial.

2026-10-15T00:00:00Z

Published in JAMA Oncol on 15 October 2026; found by the roadmap watch for ClarIDHy.

15 October 2026, JAMA Oncol.

On OnCo: ClarIDHy, Epigenetic therapy roadmap: loosening silenced genes → mutation-specific enzymes → editing the epigenome

Paper: Cabergoline Suppresses Postpartum Breast Cancer by Enhancing Mammary Gland Involution in Brca1-Mutant Mice and Is Associated with Reduced Risk in Younger Women.

2026-10-15T00:00:00Z

Published in Cancer Discov on 15 October 2026; matched the OnCo record for Cabergoline.

15 October 2026, Cancer Discov.

On OnCo: Cabergoline

Paper: Erratum for the Research Article "Enabling sustainable supply of the essential cancer medicines etoposide and teniposide in yeast".

2026-10-15T00:00:00Z

Published in Science on 15 October 2026; matched the OnCo record for Teniposide.

15 October 2026, Science.

On OnCo: Teniposide

Paper: Gastric and oesophageal cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up.

2026-10-15T00:00:00Z

Published in Ann Oncol on 15 October 2026; matched the OnCo record for Oesophageal cancer.

15 October 2026, Ann Oncol.

On OnCo: Oesophageal cancer

Approval: FDA approves atezolizumab in combination with chemotherapy for Stage III mismatch repair deficient colon cancer

2026-10-08T00:00:00Z

On October 8, 2026, the Food and Drug Administration approved atezolizumab (Tecentriq, Genentech, Inc.) in combination with a fluoropyrimidine and oxaliplatin for the adjuvant treatment of adult and pediatric patients two years of age and older with Stage III mismatch repair deficient (dMMR) colon cancer.

8 October 2026, FDA.

On OnCo: Atezolizumab, Oxaliplatin, Colon cancer

Paper: Acute activation of autophagy enables growth plate regeneration following radiation-induced injury.

2026-10-21T00:00:00Z

Published on 21 October 2026 after first appearing as a preprint; matched Cxbladder, PSMC4 and RPS6.

21 October 2026.

On OnCo: Cxbladder, PSMC4, RPS6, SOX9, SQSTM1

Paper: Antimicrobial resistance and documented empirical antibiotic prescribing among cancer patients with culture-confirmed infections at a tertiary referral hospital in Rwanda, 2019-2024.

2026-10-21T00:00:00Z

Published on 21 October 2026 after first appearing as a preprint; matched EDNRA.

21 October 2026.

On OnCo: EDNRA

Paper: ASCL1 and OLIG2 Expression Dynamics Control Glial Cell Fate and Regional Diversity in the Dorsal Forebrain.

2026-10-21T00:00:00Z

Published on 21 October 2026 after first appearing as a preprint; matched State, ASCL1 and OLIG2.

21 October 2026.

On OnCo: State, ASCL1, OLIG2

Paper: Astragali Radix-Curcumae Rhizoma synergistically potentiates 5-fluorouracil antitumor efficacy in colorectal cancer by disrupting DNA repair-cell cycle coordination.

2026-10-21T00:00:00Z

Published on 21 October 2026 after first appearing as a preprint; matched RNA sequencing & expression profiling, AKT and BRCA1 / BRCA2.

21 October 2026.

On OnCo: RNA sequencing & expression profiling, AKT, BRCA1 / BRCA2, Fluorouracil, Mismatch repair proteins, MSH2

Paper: BCG vaccination mitigates tau pathology and restores cognitive function in PS19 mice.

2026-10-21T00:00:00Z

Published on 21 October 2026 after first appearing as a preprint; matched MRI, RNA sequencing & expression profiling and State.

21 October 2026.

On OnCo: MRI, RNA sequencing & expression profiling, State, CD80

Paper: CD28 costimulation is organized by signaling condensates and counteracted by PD-1.

2026-10-21T00:00:00Z

Published on 21 October 2026 after first appearing as a preprint; matched PD-1, SRC family kinases and CD28.

21 October 2026.

On OnCo: PD-1, SRC family kinases, CD28, LCK, GRB2

Paper: Cell DiffErential Expression by Pooling (CellDEEP) highlights issues in differential gene expression in scRNA-seq.

2026-10-21T00:00:00Z

Published on 21 October 2026 after first appearing as a preprint; matched RNA sequencing & expression profiling and Single-cell & spatial profiling.

21 October 2026.

On OnCo: RNA sequencing & expression profiling, Single-cell & spatial profiling

Paper: Cytokine-Mediated Plasticity in the Molecular Requirements for Peptide-Loading Complex Formation and Antigen Presentation.

2026-10-21T00:00:00Z

Published on 21 October 2026 after first appearing as a preprint; matched Proteomics & phosphoproteomics and HLA-A.

21 October 2026.

On OnCo: Proteomics & phosphoproteomics, HLA-A

Paper: Deep dynamical models of single-cell multiomic velocities predict loss-of-function and rescue perturbations in B cells.

2026-10-21T00:00:00Z

Published on 21 October 2026 after first appearing as a preprint; matched Single-cell & spatial profiling, State and ARID1A.

21 October 2026.

On OnCo: Single-cell & spatial profiling, State, ARID1A, STAT3, CTCF, BCL6

Paper: High-content morphological profiling by Cell Painting in 3D spheroids.

2026-10-21T00:00:00Z

Published on 21 October 2026 after first appearing as a preprint; matched Single-cell & spatial profiling, PARP inhibitors and Olaparib.

21 October 2026.

On OnCo: Single-cell & spatial profiling, PARP inhibitors, Olaparib, Fluorouracil

Paper: HRDPath: an explainable multi-model deep learning architecture for predicting homologous recombination deficiency from histopathology images.

2026-10-21T00:00:00Z

Published on 21 October 2026 after first appearing as a preprint; matched HRD & BRCA testing and BRCA1 / BRCA2.

21 October 2026.

On OnCo: HRD & BRCA testing, BRCA1 / BRCA2

Paper: Improved Calreticulin Nanobody by Framework Engineering.

2026-10-21T00:00:00Z

Published on 21 October 2026 after first appearing as a preprint; matched HER2 and CALR.

21 October 2026.

On OnCo: HER2, CALR

Paper: Interferon-Induced Protein 6 (IFI6): Biological Functions, Molecular Mechanisms and Pathological Roles in Human Diseases.

2026-10-21T00:00:00Z

Published on 21 October 2026 after first appearing as a preprint; matched EGFR, AKT and BCL-2.

21 October 2026.

On OnCo: EGFR, AKT, BCL-2, Tretinoin, BIM, EGF

Issue: OnCo weekly, 2026-10-21

2026-10-21T00:00:00Z

1030 changelog entries, 1 upcoming date, 1 correction.

21 October 2026, OnCo weekly issue.

Paper: PCGF1 Promotes the Tumorigenesis of Malignancies Through Upregulating CCDC34 in Glioma.

2026-10-21T00:00:00Z

Published on 21 October 2026 after first appearing as a preprint; matched RNA sequencing & expression profiling and SET.

21 October 2026.

On OnCo: RNA sequencing & expression profiling, SET

Paper: Single-cell-level digital twins for preterm birth prevention strategies.

2026-10-21T00:00:00Z

Published on 21 October 2026 after first appearing as a preprint; matched Single-cell & spatial profiling, Atlas and mTOR.

21 October 2026.

On OnCo: Single-cell & spatial profiling, Atlas, mTOR, CD4, Aspirin

Paper: Divergent genomic evolution in astrocytomas and oligodendrogliomas.

2026-10-14T00:00:00Z

Published in Nature on 14 October 2026; matched the OnCo record for CDKN2B.

14 October 2026, Nature.

On OnCo: CDKN2B

Paper: Dose-Escalated Focal Salvage High-Dose-Rate Brachytherapy and Genomic Classifier Risk Stratification in Radiorecurrent Prostate Cancer: The F-SHARP Phase I/II Clinical Trial.

2026-10-14T00:00:00Z

Published in J Clin Oncol on 14 October 2026; matched the OnCo record for High-dose-rate brachytherapy.

14 October 2026, J Clin Oncol.

On OnCo: High-dose-rate brachytherapy

Paper: Elp1 is required for myeloid differentiation and brain repopulation.

2026-10-14T00:00:00Z

Published in Nature on 14 October 2026; matched the OnCo record for ELP1.

14 October 2026, Nature.

On OnCo: ELP1

Paper: Emerging Therapeutic targets and Early-phase drug Development in Gynecological Malignancies.

2026-10-14T00:00:00Z

Published in Ann Oncol on 14 October 2026; matched the OnCo record for WEE1.

14 October 2026, Ann Oncol.

On OnCo: WEE1, WRN helicase

Paper: Personalized neoantigen-targeting cancer vaccines in ovarian cancer: a phase 1 trial.

2026-10-14T00:00:00Z

Published in Nat Med on 14 October 2026; matched the OnCo record for NeoVax.

14 October 2026, Nat Med.

On OnCo: NeoVax, Platinum-sensitive ovarian cancer

Paper: Selpercatinib in Pediatric and Adolescent Patients With RET-Altered Solid Tumors: Safety and Efficacy Results From the Phase I/II LIBRETTO-121 Study.

2026-10-14T00:00:00Z

Published in J Clin Oncol on 14 October 2026; matched the OnCo record for Selpercatinib.

14 October 2026, J Clin Oncol.

On OnCo: Selpercatinib

Paper: Talazoparib plus enzalutamide in high-volume metastatic hormone-naive prostate cancer: a randomized phase 2 trial.

2026-10-14T00:00:00Z

Published in Nat Med on 14 October 2026; matched the OnCo record for Talazoparib.

14 October 2026, Nat Med.

On OnCo: Talazoparib

Paper: Treatment of Advanced Biliary Tract Cancer: ASCO Living Guideline, Version 2026.1.0.

2026-10-14T00:00:00Z

Published in J Clin Oncol on 14 October 2026; matched the OnCo record for NRG1.

14 October 2026, J Clin Oncol.

On OnCo: NRG1

Approval: FDA approves tucatinib with trastuzumab and pertuzumab for the maintenance treatment of HER2-positive breast cancer

2026-10-07T00:00:00Z

On October 7, 2026, the Food and Drug Administration approved tucatinib (Tukysa, Seagen Inc., a subsidiary of Pfizer) in combination with trastuzumab and pertuzumab for the maintenance treatment of adults with unresectable locally advanced or metastatic HER2-positive breast cancer following induction treatment.

7 October 2026, FDA.

On OnCo: Trastuzumab, Pertuzumab, Tucatinib, HER2-positive breast cancer, Breast cancer

Preprint: Value of Air-Flush Recovery (ATR) of Needle-Tract Residual Tissue for Establishing Pancreatic Cancer Organoids via EUS-FNA

2026-10-27T00:00:00Z

Posted on Preprints.org on 27 October 2026; not peer reviewed; matched Ultrasound, Patient-derived organoids and ATR.

27 October 2026, Preprints.org.

On OnCo: Ultrasound, Patient-derived organoids, ATR, CCDC6

Preprint: A preregistered test that outcome-permuted data also pass: mathematical coupling in a pan-cancer analysis of proliferation adjustment in prognostic gene expression studies

2026-10-27T00:00:00Z

Posted on Research Square on 27 October 2026; not peer reviewed; matched MET and SET.

27 October 2026, Research Square.

On OnCo: MET, SET

Preprint: A Single-Arm Phase II Clinical Study of SBRT Combined with Tislelizumab and GM-CSF for Advanced Non-Small Cell Lung Cancer Progressing After Immunotherapy

2026-10-27T00:00:00Z

Posted on Research Square on 27 October 2026; not peer reviewed; matched Tislelizumab, Nintedanib and SBRT / SABR.

27 October 2026, Research Square.

On OnCo: Tislelizumab, Nintedanib, SBRT / SABR, Immune checkpoint inhibitors

Preprint: Abnormal Uterine Bleeding in Female Kidney Transplant Recipients: A Cross-Sectional Study Using the FIGO PALM- COEIN Classification

2026-10-27T00:00:00Z

Posted on Research Square on 27 October 2026; not peer reviewed; matched Prednisone and mTOR.

27 October 2026, Research Square.

On OnCo: Prednisone, mTOR

Preprint: Advances and Translational Challenges in mRNA–Lipid Nanoparticle Vaccines Against Helicobacter pylori: From Rational Antigen Design to Mucosal Immunity

2026-10-27T00:00:00Z

Posted on Preprints.org on 27 October 2026; not peer reviewed; matched Azacitidine, Decitabine + cedazuridine and Tretinoin.

27 October 2026, Preprints.org.

On OnCo: Azacitidine, Decitabine + cedazuridine, Tretinoin, CD4, CD8

Preprint: Amino Acid Remodeling Precedes Malignant Transformation in Oral Epithelial Cells

2026-10-27T00:00:00Z

Posted on bioRxiv on 27 October 2026; not peer reviewed; matched Azacitidine, Decitabine + cedazuridine and Proteomics & phosphoproteomics.

27 October 2026, bioRxiv.

On OnCo: Azacitidine, Decitabine + cedazuridine, Proteomics & phosphoproteomics, Chemoprevention & risk-reducing surgery, State, CCDC6

Preprint: An Upgraded Arsenic Trioxide–Based Salvage Regimen for Relapsed or Refractory Neuroblastoma: Improved Disease Control and Genomic Alterations

2026-10-27T00:00:00Z

Posted on Research Square on 27 October 2026; not peer reviewed; matched ALK, Arsenic trioxide and MYCN.

27 October 2026, Research Square.

On OnCo: ALK, Arsenic trioxide, MYCN, Quantitative imaging biomarkers

Preprint: Anti-Nucleolin Aptamer iSN04 Inhibits Alveolar Rhabdomyosarcoma Cell Growth by Inducing Myogenic Differentiation

2026-10-27T00:00:00Z

Posted on bioRxiv on 27 October 2026; not peer reviewed; matched Vincristine, ID3 and CASZ1.

27 October 2026, bioRxiv.

On OnCo: Vincristine, ID3, CASZ1

Preprint: Application of a Multimodal Prehabilitaion and Rehabilitaion Program for Patients Undergoing Liver Cancer Resection

2026-10-27T00:00:00Z

Posted on Research Square on 27 October 2026; not peer reviewed; matched Azacitidine, Decitabine + cedazuridine and MET.

27 October 2026, Research Square.

On OnCo: Azacitidine, Decitabine + cedazuridine, MET

Preprint: Assessment of the Clinical Role of Serum Levels of IL-1, VEGF, and MMP-2 in the Detection of Radiation Pneumonitis and Prediction of Its Occurrence in Breast Cancer Females Treated with Radiotherapy

2026-10-27T00:00:00Z

Posted on Research Square on 27 October 2026; not peer reviewed; matched MMP2.

27 October 2026, Research Square.

On OnCo: MMP2

Preprint: Astatine-211 injury induces an immunostimulatory melanoma-cell state and promotes systemic antitumor immunity

2026-10-27T00:00:00Z

Posted on bioRxiv on 27 October 2026; not peer reviewed; matched RNA sequencing & expression profiling, Targeted alpha therapy and Etoposide.

27 October 2026, bioRxiv.

On OnCo: RNA sequencing & expression profiling, Targeted alpha therapy, Etoposide, State

Preprint: CATFISHR: integration of transcriptome and inferred CNV profiles for comprehensive malignant cell identification

2026-10-27T00:00:00Z

Posted on bioRxiv on 27 October 2026; not peer reviewed; matched RNA sequencing & expression profiling, Single-cell & spatial profiling and MRD / molecular residual disease testing.

27 October 2026, bioRxiv.

On OnCo: RNA sequencing & expression profiling, Single-cell & spatial profiling, MRD / molecular residual disease testing, Spatial transcriptomics

Preprint: CBX3 Deletion Overcomes Ferroptosis Resistance in Colorectal Cancer by Targeting IFNγ/SLC7A11/SLC3A2 Axis

2026-10-27T00:00:00Z

Posted on bioRxiv on 27 October 2026; not peer reviewed; matched COX-2 and STAT1.

27 October 2026, bioRxiv.

On OnCo: COX-2, STAT1

Preprint: Cell-type resolved prenylomics in mouse liver enabled by a low-input proteomics workflow

2026-10-27T00:00:00Z

Posted on bioRxiv on 27 October 2026; not peer reviewed; matched Pertuzumab and Proteomics & phosphoproteomics.

27 October 2026, bioRxiv.

On OnCo: Pertuzumab, Proteomics & phosphoproteomics

Preprint: Computational Design and Evaluation of De Novo Protein Minibinders Targeting Specific Sites of STAT3

2026-10-27T00:00:00Z

Posted on bioRxiv on 27 October 2026; not peer reviewed; matched STAT3.

27 October 2026, bioRxiv.

On OnCo: STAT3

Preprint: Cranial Nerve Outcomes After Primary or Adjuvant Gamma Knife Stereotactic Radiosurgery for Cavernous Sinus Meningiomas

2026-10-27T00:00:00Z

Posted on Research Square on 27 October 2026; not peer reviewed; matched NT5C2, Stereotactic radiosurgery and Gamma Knife.

27 October 2026, Research Square.

On OnCo: NT5C2, Stereotactic radiosurgery, Gamma Knife

Preprint: CRISPR/Cas9-mediated knockout of AKAP12 gene increases susceptibility to doxorubicin in MCF-7/ADR breast cancer cell line

2026-10-27T00:00:00Z

Posted on Research Square on 27 October 2026; not peer reviewed; matched Doxorubicin.

27 October 2026, Research Square.

On OnCo: Doxorubicin

Preprint: Development and Temporal Validation of an Interpretable Machine‑Learning Model for Risk‑Stratified Endoscopy Triage in Population‑Based Esophageal Squamous Cell Carcinoma Screening

2026-10-27T00:00:00Z

Posted on Research Square on 27 October 2026; not peer reviewed; matched Azacitidine, Decitabine + cedazuridine and Cxbladder.

27 October 2026, Research Square.

On OnCo: Azacitidine, Decitabine + cedazuridine, Cxbladder

Preprint: Diagnostic Challenges in Atypical Spindle Cell Melanoma Simulating Malignant Peripheral Nerve Sheath Tumor

2026-10-27T00:00:00Z

Posted on Research Square on 27 October 2026; not peer reviewed; matched BRAF, NRAS and NF1.

27 October 2026, Research Square.

On OnCo: BRAF, NRAS, NF1, SOX10, CD34

Preprint: Disease-associated NK-cell state remodeling reveals transcriptional profiles predictive of clinical phenotypes

2026-10-27T00:00:00Z

Posted on bioRxiv on 27 October 2026; not peer reviewed; matched Immune checkpoint inhibitors.

27 October 2026, bioRxiv.

On OnCo: Immune checkpoint inhibitors

Preprint: Divide and conquer: a viral bifunctional RNA utilizes both RNA and protein to modulate pro-tumourigenic pathways

2026-10-27T00:00:00Z

Posted on bioRxiv on 27 October 2026; not peer reviewed; matched YES1.

27 October 2026, bioRxiv.

On OnCo: YES1

Preprint: Educational expectations and needs of individuals scheduled for breast surgery within the Primary Nursing Model: a qualitative study

2026-10-27T00:00:00Z

Posted on medRxiv on 27 October 2026; not peer reviewed; matched CCDC6.

27 October 2026, medRxiv.

On OnCo: CCDC6

Preprint: Etanercept Withdrawal-Associated Regression of Nodal Marginal Zone Lymphoma in Rheumatoid Arthritis

2026-10-27T00:00:00Z

Posted on Research Square on 27 October 2026; not peer reviewed; matched Methotrexate.

27 October 2026, Research Square.

On OnCo: Methotrexate

Preprint: Evaluation of Optical-Spectroscopy Based Identification of Breast Abnormality / Lumps in Indian Population Using Brexwel Device

2026-10-27T00:00:00Z

Posted on Preprints.org on 27 October 2026; not peer reviewed; matched Mammography & tomosynthesis and CCDC6.

27 October 2026, Preprints.org.

On OnCo: Mammography & tomosynthesis, CCDC6

Preprint: Extracellular vesicle-associated COMP from cancer-associated fibroblasts promotes ferroptosis resistance in hepatocellular carcinoma

2026-10-27T00:00:00Z

Posted on Research Square on 27 October 2026; not peer reviewed; matched HIF-1α and RANBP2.

27 October 2026, Research Square.

On OnCo: HIF-1α, RANBP2

Preprint: Factors Associated with Response to 177Lu-PSMA-617 Radioligand Therapy in Metastatic Castration-Resistant Prostate Cancer: A Retrospective Analysis

2026-10-27T00:00:00Z

Posted on Research Square on 27 October 2026; not peer reviewed; matched PET/CT, PSMA PET and Radioligand therapy.

27 October 2026, Research Square.

On OnCo: PET/CT, PSMA PET, Radioligand therapy, Lutetium-177 radioligand therapy, PSMA, Lutetium-177 vipivotide tetraxetan

Preprint: Faecal Microbiota Transplantation in Paediatric Haematopoietic Stem Cell Transplantation: Current Evidence, Safety, and Future Directions

2026-10-27T00:00:00Z

Posted on Preprints.org on 27 October 2026; not peer reviewed; matched CCDC6.

27 October 2026, Preprints.org.

On OnCo: CCDC6

Preprint: Favorable Survival and Manageable Toxicity With Consolidative Radiotherapy to the Residual Primary Tumor After First-Line Chemoimmunotherapy in Metastatic NSCLC

2026-10-27T00:00:00Z

Posted on Research Square on 27 October 2026; not peer reviewed; matched Nintedanib.

27 October 2026, Research Square.

On OnCo: Nintedanib

Preprint: First-in-Human Phase 1/2 Study of Cafelkibart, an Anti-CCR8 Monoclonal Antibody, as Monotherapy or in Combination with PD-1 Inhibition in Solid Tumors

2026-10-27T00:00:00Z

Posted on Research Square on 27 October 2026; not peer reviewed; matched Monoclonal antibodies and PD-1.

27 October 2026, Research Square.

On OnCo: Monoclonal antibodies, PD-1

Preprint: First-in-human quad-targeting CAR T cells for diffuse intrinsic pontine glioma: a phase 1 trial

2026-10-27T00:00:00Z

Posted on Research Square on 27 October 2026; not peer reviewed; matched CAR-T cell therapy, HER2 and B7-H3.

27 October 2026, Research Square.

On OnCo: CAR-T cell therapy, HER2, B7-H3, H3C14

Preprint: From non-uptake during early adolescence to acceptance during a catch-up campaign: a qualitative study of changing HPV vaccination decisions across two life stages among young women in Amsterdam, the Netherlands

2026-10-27T00:00:00Z

Posted on medRxiv on 27 October 2026; not peer reviewed; matched HPV & HBV vaccination.

27 October 2026, medRxiv.

On OnCo: HPV & HBV vaccination

Preprint: Genetic drivers shape TREM2-dependent myeloid responses and glioblastoma progression

2026-10-27T00:00:00Z

Posted on bioRxiv on 27 October 2026; not peer reviewed; matched RNA sequencing & expression profiling, Single-cell & spatial profiling and State.

27 October 2026, bioRxiv.

On OnCo: RNA sequencing & expression profiling, Single-cell & spatial profiling, State, NF1, PDGFB

Preprint: Giant High-Grade Myxofibrosarcoma of the Right Thigh Treated by Hip Disarticulation: A Case Report with Imaging–Pathology Correlation

2026-10-27T00:00:00Z

Posted on Research Square on 27 October 2026; not peer reviewed; matched Ifosfamide.

27 October 2026, Research Square.

On OnCo: Ifosfamide

Preprint: Heptyl prodigiosin from estuarine Zooshikella sp. RANM57 induces caspase-dependent apoptosis and suppresses clonogenic survival in androgen-independent prostate cancer cells

2026-10-27T00:00:00Z

Posted on Research Square on 27 October 2026; not peer reviewed; matched Cisplatin and Platinum agents.

27 October 2026, Research Square.

On OnCo: Cisplatin, Platinum agents

Preprint: Impact of Surgical Timing on Outcomes in Locally Advanced Rectal Cancer: A Retrospective Study in a Resource-Limited Setting

2026-10-27T00:00:00Z

Posted on Research Square on 27 October 2026; not peer reviewed; matched ELL.

27 October 2026, Research Square.

On OnCo: ELL

Preprint: Inferring somatic copy number aberrations from spatial transcriptomics data to study early cancer development

2026-10-27T00:00:00Z

Posted on bioRxiv on 27 October 2026; not peer reviewed; matched Single-cell & spatial profiling and Spatial transcriptomics.

27 October 2026, bioRxiv.

On OnCo: Single-cell & spatial profiling, Spatial transcriptomics

Preprint: Integrated single cell and bulk transcriptomic analysis reveals disulfidptosis related malignant epithelial states associated with prognosis in gastric cancer

2026-10-27T00:00:00Z

Posted on Research Square on 27 October 2026; not peer reviewed; matched RNA sequencing & expression profiling and Single-cell & spatial profiling.

27 October 2026, Research Square.

On OnCo: RNA sequencing & expression profiling, Single-cell & spatial profiling

Preprint: Integrative Single-Cell Transcriptomics and Explainable AI for Disease Mechanism and Biomarker Discovery in Triple-Negative Breast Cancer

2026-10-27T00:00:00Z

Posted on bioRxiv on 27 October 2026; not peer reviewed; matched RNA sequencing & expression profiling, Single-cell & spatial profiling and KRAS.

27 October 2026, bioRxiv.

On OnCo: RNA sequencing & expression profiling, Single-cell & spatial profiling, KRAS, State, TGFBR2, WWTR1

Preprint: Juvenile Xanthogranuloma in a Child: A Case Report

2026-10-27T00:00:00Z

Posted on Research Square on 27 October 2026; not peer reviewed; matched Cobimetinib, MRI and Capmatinib.

27 October 2026, Research Square.

On OnCo: Cobimetinib, MRI, Capmatinib, CD163

Preprint: Lymphoma response to chimeric antigen receptor T cell therapy is driven by endogenous tumor-reactive CD8⁺ T cells

2026-10-27T00:00:00Z

Posted on bioRxiv on 27 October 2026; not peer reviewed; matched CAR-T cell therapy, CD19 and CD58.

27 October 2026, bioRxiv.

On OnCo: CAR-T cell therapy, CD19, CD58, CD8

Paper: Activity of Low Dose Nivolumab in Patients With Advanced Squamous Cell Carcinomas and Other Cancers.

2026-10-20T00:00:00Z

Published on 20 October 2026 after first appearing as a preprint; matched Immune checkpoint inhibitors, PD-1 and Nivolumab.

20 October 2026.

On OnCo: Immune checkpoint inhibitors, PD-1, Nivolumab

Paper: Asymmetric crosstalk between the BMP and TGF-β pathways resolves signaling ambiguity.

2026-10-20T00:00:00Z

Published on 20 October 2026 after first appearing as a preprint; matched Mathematical models of cancer.

20 October 2026.

On OnCo: Mathematical models of cancer

Paper: External Validation of MRI-Based Prostate Cancer Risk Calculators in a Contemporary Pre-Biopsy mpMRI Cohort.

2026-10-20T00:00:00Z

Published on 20 October 2026 after first appearing as a preprint; matched Multiparametric prostate MRI and MRI.

20 October 2026.

On OnCo: Multiparametric prostate MRI, MRI

Paper: Herpesviruses show consistency in their nuclear egress-associated induction of lamina-depleted areas as measured in an autofluorescent reporter cell model.

2026-10-20T00:00:00Z

Published on 20 October 2026 after first appearing as a preprint; matched LMNA.

20 October 2026.

On OnCo: LMNA

Paper: Impact of Opt-Out Versus Opt-In Recruitment on Engagement of FDNY WTC-Exposed Responders in a Tobacco Cessation Intervention.

2026-10-20T00:00:00Z

Published in Subst Use Addctn J on 20 October 2026; found by the roadmap watch for OPT-IN.

20 October 2026, Subst Use Addctn J.

On OnCo: OPT-IN, Gallbladder cancer roadmap: from a chance finding at gallstone surgery to a disease with its own trials

Paper: Loss of LanC-like proteins delays post-injury regeneration of aging skeletal muscles.

2026-10-20T00:00:00Z

Published on 20 October 2026 after first appearing as a preprint; matched PAX7.

20 October 2026.

On OnCo: PAX7

Paper: LRH-1 is a novel regulator of neutrophil-driven immune responses within the tumor microenvironment.

2026-10-20T00:00:00Z

Published on 20 October 2026 after first appearing as a preprint; matched NR5A2 and CD4.

20 October 2026.

On OnCo: NR5A2, CD4

Paper: MEDA-PKD: a dynamic, real-time analytics platform for precision care in autosomal dominant polycystic kidney disease.

2026-10-20T00:00:00Z

Published on 20 October 2026 after first appearing as a preprint; matched Proteomics & phosphoproteomics and EGFR.

20 October 2026.

On OnCo: Proteomics & phosphoproteomics, EGFR

Paper: MG53 suppresses the progression of bladder cancer through E3 ubiquitin ligase-mediated degradation of AMPKα.

2026-10-20T00:00:00Z

Published on 20 October 2026 after first appearing as a preprint; matched BCL-2 and BAX.

20 October 2026.

On OnCo: BCL-2, BAX

Paper: Selective persistence of HIV-1-infected T cell clones can occur through immune reprogramming driven by defective, transcriptionally active proviruses.

2026-10-20T00:00:00Z

Published on 20 October 2026 after first appearing as a preprint; matched STAT5, BACH2 and CD4.

20 October 2026.

On OnCo: STAT5, BACH2, CD4

Paper: Transient ATM inhibition enhances knock-in efficiency in hematopoietic stem cells by attenuating the DNA damage response.

2026-10-20T00:00:00Z

Published on 20 October 2026 after first appearing as a preprint; matched Whole-exome & whole-genome sequencing and ATM.

20 October 2026.

On OnCo: Whole-exome & whole-genome sequencing, ATM

Paper: Vcam1 in endothelial and stromal cells regulates hematopoietic stem cell contact with the niche.

2026-10-20T00:00:00Z

Published on 20 October 2026 after first appearing as a preprint; matched Mesenchymal stromal cells for tissue damage.

20 October 2026.

On OnCo: Mesenchymal stromal cells for tissue damage

Paper: An imprecise label in the era of precision medicine: labelling and access for daraxonrasib, the first pan-RAS inhibitor approval.

2026-10-13T00:00:00Z

Published in Nat Rev Clin Oncol on 13 October 2026; matched the OnCo record for Daraxonrasib.

13 October 2026, Nat Rev Clin Oncol.

On OnCo: Daraxonrasib

Paper: Germline DDX41 defines a distinct subgroup in MDS undergoing transplantation with reduced relapse and improved survival.

2026-10-13T00:00:00Z

Published in Blood on 13 October 2026; matched the OnCo record for DDX41.

13 October 2026, Blood.

On OnCo: DDX41

Paper: Molecular Consequences and Targeting of PPM1D Overexpression in Myeloproliferative Neoplasms.

2026-10-13T00:00:00Z

Published in Blood on 13 October 2026; matched the OnCo record for PPM1D.

13 October 2026, Blood.

On OnCo: PPM1D

Paper: VERIFY: A Phase III Trial of Rusfertide Versus Placebo in Phlebotomy-Dependent Patients With Polycythemia Vera Receiving Standard-of-Care Therapy.

2026-10-13T00:00:00Z

Published in J Clin Oncol on 13 October 2026; matched the OnCo record for Rusfertide.

13 October 2026, J Clin Oncol.

On OnCo: Rusfertide

Paper: Activation of the endocytosis pathway stratifies subtypes and therapeutic sensitivity in colorectal cancer.

2026-10-19T00:00:00Z

Published on 19 October 2026 after first appearing as a preprint; matched EGFR.

19 October 2026.

On OnCo: EGFR

Paper: Aging-related morphological changes in the obturator internus and levator ani.

2026-10-19T00:00:00Z

Published on 19 October 2026 after first appearing as a preprint; matched MRI.

19 October 2026.

On OnCo: MRI

Paper: Claims-based frailty, dual eligibility, and potential unmet home-health needs in older breast cancer survivors.

2026-10-19T00:00:00Z

Published in J Natl Cancer Inst on 19 October 2026; matched the OnCo record for CREB3L1.

19 October 2026, J Natl Cancer Inst.

On OnCo: CREB3L1, Frailty and late effects in survivors

Paper: Delayed and selective bone health assessment following cancer diagnosis: a real-world gap in survivorship care.

2026-10-19T00:00:00Z

Published on 19 October 2026 after first appearing as a preprint; matched Immune checkpoint inhibitors, MET and ELL.

19 October 2026.

On OnCo: Immune checkpoint inhibitors, MET, ELL

Paper: Divergent Human Papillomavirus Genotype Spectra in Three Indigenous Communities of Venezuela: Implications for Vaccine Choice and Cervical Screening.

2026-10-19T00:00:00Z

Published on 19 October 2026 after first appearing as a preprint; matched HPV & HBV vaccination, Cxbladder and PSMB6.

19 October 2026.

On OnCo: HPV & HBV vaccination, Cxbladder, PSMB6

Paper: Identification and characterization of neoplastic cells in keratin-positive giant cell-rich tumors.

2026-10-19T00:00:00Z

Published on 19 October 2026 after first appearing as a preprint; matched RNA sequencing & expression profiling, Single-cell & spatial profiling and Spatial transcriptomics.

19 October 2026.

On OnCo: RNA sequencing & expression profiling, Single-cell & spatial profiling, Spatial transcriptomics, CSF1R, CSF1, NCOR2

Paper: Large-scale association study identifies lung cancer susceptibility copy number variants and their potential functional role in genetic instability.

2026-10-19T00:00:00Z

Published on 19 October 2026 after first appearing as a preprint; matched Oligonucleotide therapeutics, PSMB8 and NFE2L2.

19 October 2026.

On OnCo: Oligonucleotide therapeutics, PSMB8, NFE2L2, CLCN6

Paper: Longitudinal Flow Cytometric Profiling of CAR-T and Endogenous T Cells Following CD19 CAR-T Therapy.

2026-10-19T00:00:00Z

Published on 19 October 2026 after first appearing as a preprint; matched Tisagenlecleucel, CAR-T cell therapy and CD19.

19 October 2026.

On OnCo: Tisagenlecleucel, CAR-T cell therapy, CD19, PD-1, TIGIT, ICANS, and whether thinking recovers after CAR-T

Paper: Opportunistic Cardiovascular Assessment During Lung Cancer Screening with Low-Dose Computed Tomography: A New Window for Prevention.

2026-10-19T00:00:00Z

Published on 19 October 2026 after first appearing as a preprint; matched CT and AI in radiology.

19 October 2026.

On OnCo: CT, AI in radiology

Paper: Sex Differences in Postoperative Outcomes for Men and Women With Colon Cancer in the US Military Health System.

2026-10-19T00:00:00Z

Published in Am J Clin Oncol on 19 October 2026; matched the OnCo record for Localised anal squamous cell carcinoma.

19 October 2026, Am J Clin Oncol.

On OnCo: Localised anal squamous cell carcinoma

Paper: Spatial polarization of endothelial ICAM-1 governs T-cell exclusion in melanoma.

2026-10-19T00:00:00Z

Published on 19 October 2026 after first appearing as a preprint; matched RNA sequencing & expression profiling, Immune checkpoint inhibitors and PD-1.

19 October 2026.

On OnCo: RNA sequencing & expression profiling, Immune checkpoint inhibitors, PD-1

Paper: Talquetamab and Its Effect on Relapsed and Refractory Multiple Myeloma.

2026-10-19T00:00:00Z

Published in Ann Afr Med on 19 October 2026; matched the OnCo record for Talquetamab.

19 October 2026, Ann Afr Med.

On OnCo: Talquetamab

Paper: Time-aligned segmental strain as a diagnostic marker for obstructive coronary artery disease in patients with chronic chest pain.

2026-10-19T00:00:00Z

Published on 19 October 2026 after first appearing as a preprint; matched CT and Strain echocardiography.

19 October 2026.

On OnCo: CT, Strain echocardiography

Paper: Acinar-Derived Organoids Reveal Stage-Specific Control of Acinar Plasticity.

2026-10-18T00:00:00Z

Published in Adv Sci (Weinh) on 18 October 2026; matched the OnCo record for IGF-1 receptor.

18 October 2026, Adv Sci (Weinh).

On OnCo: IGF-1 receptor

Paper: Adjuvant Systemic Therapies After Nephrectomy for Renal Cell Carcinoma: A Bayesian Network Meta-Analysis and Multi-Criteria Benefit-Risk Assessment.

2026-10-18T00:00:00Z

Published in Target Oncol on 18 October 2026; matched the OnCo record for Belzutifan.

18 October 2026, Target Oncol.

On OnCo: Belzutifan

Paper: Age Does Not Independently Predict Biochemical Recurrence in Prostate Cancer Following Radical Prostatectomy: A Comparative Analysis of 4223 pT2N0R0 Patients.

2026-10-18T00:00:00Z

Published in Prostate on 18 October 2026; matched the OnCo record for Localised penile cancer.

18 October 2026, Prostate.

On OnCo: Localised penile cancer, Biochemical recurrence of prostate cancer

Paper: An Integrated Approach to MSI-High Colorectal Cancer Therapy in a Young Patient: A Clinical Case.

2026-10-18T00:00:00Z

Published in Am J Case Rep on 18 October 2026; matched the OnCo record for FOLFOX.

18 October 2026, Am J Case Rep.

On OnCo: FOLFOX

Paper: Autoimmune Inner Ear Disease: The Current State of Knowledge.

2026-10-18T00:00:00Z

Published on 18 October 2026 after first appearing as a preprint; matched State.

18 October 2026.

On OnCo: State

Paper: Characterization of the morphological, immunophenotypical and cytogenetic features of high-grade B-cell lymphoma with 11q aberration.

2026-10-18T00:00:00Z

Published in Histopathology on 18 October 2026; matched the OnCo record for Burkitt lymphoma.

18 October 2026, Histopathology.

On OnCo: Burkitt lymphoma, DDX3X

Paper: Circulating α-Klotho Is Elevated in Breast Cancer and Positively Correlates with IGF-1.

2026-10-18T00:00:00Z

Published on 18 October 2026 after first appearing as a preprint; matched HER2, Estrogen receptor and Progesterone receptor.

18 October 2026.

On OnCo: HER2, Estrogen receptor, Progesterone receptor

Paper: Comparison of cardiovascular events in patients with metastatic hormone sensitive prostate cancer treated with LHRH agonists to LHRH antagonists in the US: A retrospective cohort study.

2026-10-18T00:00:00Z

Published in Urol Oncol on 18 October 2026; matched the OnCo record for Degarelix.

18 October 2026, Urol Oncol.

On OnCo: Degarelix, Metastatic hormone-sensitive prostate cancer, Relugolix, Triptorelin

Paper: Foundation Model-Enabled Pathology-Informed MRI Model for Preoperative Prediction of Vessels Encapsulating Tumor Clusters in Resectable Hepatocellular Carcinoma: A Multicenter Retrospective Study.

2026-10-18T00:00:00Z

Published in Adv Sci (Weinh) on 18 October 2026; matched the OnCo record for Pathology & radiology foundation models.

18 October 2026, Adv Sci (Weinh).

On OnCo: Pathology & radiology foundation models

Paper: HIV-1 diagnosis during pre-exposure prophylaxis: A case report.

2026-10-18T00:00:00Z

Published in Int J STD AIDS on 18 October 2026; matched the OnCo record for Follicular thyroid cancer.

18 October 2026, Int J STD AIDS.

On OnCo: Follicular thyroid cancer

Paper: MDL-001: An Oral, Direct-Acting Broad-Spectrum Antiviral for Influenza-like Illness (ILI) and Chronic Hepatitis In Vivo.

2026-10-18T00:00:00Z

Published on 18 October 2026 after first appearing as a preprint; matched Pertuzumab, Azacitidine and Decitabine + cedazuridine.

18 October 2026.

On OnCo: Pertuzumab, Azacitidine, Decitabine + cedazuridine

Paper: Multifunctional Magneto‑Thermal Probe Enhances the Efficacy of Tumor Therapy as a Tumor Nanovaccine.

2026-10-18T00:00:00Z

Published in Small on 18 October 2026; matched the OnCo record for TIL therapy.

18 October 2026, Small.

On OnCo: TIL therapy

Paper: Perioperative Hemoglobin Decline After Deep Endometriosis Surgery: Association with Surgery Duration and Exploratory Analyses of Operative Extent.

2026-10-18T00:00:00Z

Published on 18 October 2026 after first appearing as a preprint; matched MET.

18 October 2026.

On OnCo: MET

Paper: PRAME Immunohistochemistry and Molecular Profiling in Undifferentiated Cutaneous Pleomorphic Neoplasms: A Case Series of 8 Tumors.

2026-10-18T00:00:00Z

Published in J Cutan Pathol on 18 October 2026; matched the OnCo record for PRAME.

18 October 2026, J Cutan Pathol.

On OnCo: PRAME

Paper: Structural characterisation and anti-hepatoma activities of an acidic polysaccharide extracted from Morinda citrifolia L. (Noni) fruits.

2026-10-18T00:00:00Z

Published in Nat Prod Res on 18 October 2026; matched the OnCo record for CASP8.

18 October 2026, Nat Prod Res.

On OnCo: CASP8

Paper: Subtype- and functional class-dependent prognostic impact of CSF3R mutations in acute myeloid leukaemia: A cohort study of 2500 patients.

2026-10-18T00:00:00Z

Published in Br J Haematol on 18 October 2026; matched the OnCo record for Acute promyelocytic leukaemia.

18 October 2026, Br J Haematol.

On OnCo: Acute promyelocytic leukaemia, CEBPA, G-CSF receptor, Pleural mesothelioma, RUNX1T1

Paper: Thioredoxin-2 Alleviates Osteoporosis by Restraining FOXO3a Nuclear Translocation.

2026-10-18T00:00:00Z

Published in Adv Sci (Weinh) on 18 October 2026; matched the OnCo record for KMT2B.

18 October 2026, Adv Sci (Weinh).

On OnCo: KMT2B

Paper: Tubocapsenolide A Overcomes Oxaliplatin Resistance in Colorectal Cancer by Targeting PLK1 to Impair CEP55-ESCRT-Associated Vesicular Damage Clearance.

2026-10-18T00:00:00Z

Published in Adv Sci (Weinh) on 18 October 2026; matched the OnCo record for PLK1.

18 October 2026, Adv Sci (Weinh).

On OnCo: PLK1

Paper: 2-Hydroxyisobutyrylation of SRSF9 Regulates CD44 Alternative Splicing to Promote Colorectal Cancer Liver Metastasis.

2026-10-17T00:00:00Z

Published in Cancer Lett on 17 October 2026; matched the OnCo record for KAT7.

17 October 2026, Cancer Lett.

On OnCo: KAT7, Ribonucleotide reductase

Paper: A degenerate Fokker-Planck stochastic modeling and simulation of the signaling pathways in esophageal cancer.

2026-10-17T00:00:00Z

Published in Math Biosci on 17 October 2026; matched the OnCo record for Appendiceal cancer and pseudomyxoma peritonei.

17 October 2026, Math Biosci.

On OnCo: Appendiceal cancer and pseudomyxoma peritonei, Low-grade appendiceal mucinous neoplasm and pseudomyxoma peritonei

Paper: A genome-wide association study of cognitive impairment in a Chinese cohort of 1,040 individuals.

2026-10-17T00:00:00Z

Published in Hum Genet on 17 October 2026; matched the OnCo record for FAT1.

17 October 2026, Hum Genet.

On OnCo: FAT1, SETBP1, STEAP1

Paper: Acupuncture versus reflexology for cancer-related pain in palliative care: a pragmatic study.

2026-10-17T00:00:00Z

Published in J Pain Symptom Manage on 17 October 2026; matched the OnCo record for Reflexology.

17 October 2026, J Pain Symptom Manage.

On OnCo: Reflexology

Paper: Addressing complex autofluorescence signatures in solid tissue samples to enhance full spectrum flow cytometry of non-immune cells.

2026-10-17T00:00:00Z

Published on 17 October 2026 after first appearing as a preprint; matched Single-cell & spatial profiling and CCDC6.

17 October 2026.

On OnCo: Single-cell & spatial profiling, CCDC6

Paper: Alteration of empathy-related behaviors in two strains of mice expressing mutations of the α5 cholinergic nicotinic receptor subunit.

2026-10-17T00:00:00Z

Published on 17 October 2026 after first appearing as a preprint; matched State and CHRNA5.

17 October 2026.

On OnCo: State, CHRNA5

Paper: Anti-N-Methyl-D-Aspartate Receptor Encephalitis With Autonomic Instability and Focal Seizures Without Detectable Ovarian Teratoma.

2026-10-17T00:00:00Z

Published in Cureus on 17 October 2026; matched the OnCo record for Human normal immunoglobulin.

17 October 2026, Cureus.

On OnCo: Human normal immunoglobulin

Paper: Association of TP53 Truncating Mutations with Time to Treatment Failure after First-Line Chemoimmunotherapy in HER2-Mutant Non-Small Cell Lung Cancer.

2026-10-17T00:00:00Z

Published in Target Oncol on 17 October 2026; matched the OnCo record for HER2-mutant non-small-cell lung cancer.

17 October 2026, Target Oncol.

On OnCo: HER2-mutant non-small-cell lung cancer, Pemetrexed

Paper: B-Lymphoblastic Leukemia Presenting as Bilateral Ovarian Masses in a 20-Year-Old Woman.

2026-10-17T00:00:00Z

Published in Clin Case Rep on 17 October 2026; matched the OnCo record for CREBBP.

17 October 2026, Clin Case Rep.

On OnCo: CREBBP, KMT2D

Paper: BRCAness-Driven Prognostic Model and Regimen-Specific Therapeutic Implications in Triple-Negative Breast Cancer With Residual Disease After Neoadjuvant Chemotherapy.

2026-10-17T00:00:00Z

Published in Int J Cancer on 17 October 2026; matched the OnCo record for HRD & BRCA testing.

17 October 2026, Int J Cancer.

On OnCo: HRD & BRCA testing

Paper: Case Report: Dose dependent intracranial response to sotorasib in KRASG12C-mutated lung cancer brain metastases.

2026-10-17T00:00:00Z

Published in Oncol Res Treat on 17 October 2026; matched the OnCo record for Sotorasib.

17 October 2026, Oncol Res Treat.

On OnCo: Sotorasib

Paper: Computational Analysis of the Homologous Mouse Double RINGs Interface for Targeted Anticancer Drug Design.

2026-10-17T00:00:00Z

Published on 17 October 2026 after first appearing as a preprint; matched MDM2.

17 October 2026.

On OnCo: MDM2

Paper: Conjunctival involvement with corneal extension in pediatric mycosis fungoides. Surgical and immunomodulatory management.

2026-10-17T00:00:00Z

Published in Arch Soc Esp Oftalmol (Engl Ed) on 17 October 2026; matched the OnCo record for Mycosis fungoides.

17 October 2026, Arch Soc Esp Oftalmol (Engl Ed).

On OnCo: Mycosis fungoides

Paper: Corrigendum to "Chinese guidelines for the diagnosis and treatment of Craniopharyngioma in children (2025)" [Cancer Lett. 659 (2026) 218784].

2026-10-17T00:00:00Z

Published in Cancer Lett on 17 October 2026; matched the OnCo record for Craniopharyngioma.

17 October 2026, Cancer Lett.

On OnCo: Craniopharyngioma

Paper: Dapagliflozin alleviates CYH33-induced hyperglycemia and preserves antitumor immunity against ovarian cancer in type 1 diabetic mice.

2026-10-17T00:00:00Z

Published in Life Sci on 17 October 2026; matched the OnCo record for Clear cell ovarian cancer.

17 October 2026, Life Sci.

On OnCo: Clear cell ovarian cancer, CYH33

Paper: Decoding radiation-induced transcriptomic signatures of human leukocytes using long-read RNA-seq: clinical and biodosimetric implications.

2026-10-17T00:00:00Z

Published on 17 October 2026 after first appearing as a preprint; matched RNA sequencing & expression profiling and RPS19.

17 October 2026.

On OnCo: RNA sequencing & expression profiling, RPS19

Paper: Dermoscopy of intraepidermal keratinocytic neoplasms in solid organ transplant recipients: a single-center prospective real-world study supported by machine learning.

2026-10-17T00:00:00Z

Published in Actas Dermosifiliogr on 17 October 2026; matched the OnCo record for Bowen's disease.

17 October 2026, Actas Dermosifiliogr.

On OnCo: Bowen's disease, Cutaneous squamous cell carcinoma

Paper: Diffuse Leptomeningeal Glioneuronal Tumor With Initial Diagnosis of Pilocytic Astrocytoma With Anaplasia: A Case Study.

2026-10-17T00:00:00Z

Published in Clin Case Rep on 17 October 2026; matched the OnCo record for Paediatric low-grade glioma.

17 October 2026, Clin Case Rep.

On OnCo: Paediatric low-grade glioma

Paper: Diverse patterns of transcriptional regulation and epigenetic reprogramming within PMDs contribute to ESCC progression by regulating EMT and immunosuppression.

2026-10-17T00:00:00Z

Published in Epigenetics on 17 October 2026; matched the OnCo record for TDO2.

17 October 2026, Epigenetics.

On OnCo: TDO2, TIM-3

Paper: Does Additional Margin Excision During Pegulicianine Fluorescence-Guided Surgery (pFGS) Affect Patient Breast Satisfaction?

2026-10-17T00:00:00Z

Published in Ann Surg Oncol on 17 October 2026; matched the OnCo record for Fluorescence-guided surgery.

17 October 2026, Ann Surg Oncol.

On OnCo: Fluorescence-guided surgery, Pegulicianine

Paper: Ectromelia Virus Reprograms the Noncanonical NF-κB Signaling Pathway in HeLa Epithelial Cells.

2026-10-17T00:00:00Z

Published in Arch Immunol Ther Exp (Warsz) on 17 October 2026; matched the OnCo record for BIRC3.

17 October 2026, Arch Immunol Ther Exp (Warsz).

On OnCo: BIRC3, NFKB2, PSIP1, SND1, TNFAIP3, TRAF3

Paper: Expert consensus on the management of peripheral neuropathy in patients with lymphoma on brentuximab vedotin.

2026-10-17T00:00:00Z

Published in Support Care Cancer on 17 October 2026; matched the OnCo record for Brentuximab vedotin.

17 October 2026, Support Care Cancer.

On OnCo: Brentuximab vedotin, CD30

Paper: Final analysis results from DREAMM-3, a phase 3 study of belantamab mafodotin versus pomalidomide plus dexamethasone in patients with relapsed/refractory multiple myeloma.

2026-10-17T00:00:00Z

Published in Blood Cancer J on 17 October 2026; matched the OnCo record for Belantamab mafodotin.

17 October 2026, Blood Cancer J.

On OnCo: Belantamab mafodotin, Pomalidomide

Paper: From MAPK Reactivation to Response: Clinical Approaches Targeting BRAF/MEK Resistance in Melanoma.

2026-10-17T00:00:00Z

Published in Am J Clin Dermatol on 17 October 2026; matched the OnCo record for ARAF.

17 October 2026, Am J Clin Dermatol.

On OnCo: ARAF, BRAF V600-mutant melanoma

Paper: Gedatolisib after CDK4/6 inhibition in HR-Positive/HER2-negative advanced breast cancer: pharmacology, phase iii evidence, and therapeutic positioning.

2026-10-17T00:00:00Z

Published in Expert Opin Pharmacother on 17 October 2026; matched the OnCo record for Fulvestrant.

17 October 2026, Expert Opin Pharmacother.

On OnCo: Fulvestrant, Gedatolisib, Palbociclib

Paper: Genetic and clinical evidence supports HLA-DR⁺ CD8⁺ T cells as a favorable immune biomarker in acute myeloid leukemia.

2026-10-17T00:00:00Z

Published in Clin Immunol on 17 October 2026; matched the OnCo record for Acute promyelocytic leukaemia.

17 October 2026, Clin Immunol.

On OnCo: Acute promyelocytic leukaemia

Paper: Genistein targets Wnt5a to alleviate temporomandibular joint osteoarthritis by suppressing JNK/JUN-dependent MMP9 activation.

2026-10-17T00:00:00Z

Published in Biochem Pharmacol on 17 October 2026; matched the OnCo record for COL2A1.

17 October 2026, Biochem Pharmacol.

On OnCo: COL2A1, Mia

Paper: Growth hormone-releasing hormone-secreting giant pheochromocytoma causing acromegaly: a case report with a review of the literature.

2026-10-17T00:00:00Z

Published in Endocr J on 17 October 2026; matched the OnCo record for Somatotroph pituitary neuroendocrine tumour.

17 October 2026, Endocr J.

On OnCo: Somatotroph pituitary neuroendocrine tumour

Paper: Healthcare resource utilization and costs of US patients with small cell lung cancer treated with second-line therapies: a retrospective real-world database study.

2026-10-17T00:00:00Z

Published in J Med Econ on 17 October 2026; matched the OnCo record for Lurbinectedin.

17 October 2026, J Med Econ.

On OnCo: Lurbinectedin, Topotecan

Paper: Identification of a novel Microbacterium species and biosynthesis of gold nanoparticles: activation of apoptosis and dysregulation of ABCG transporters in gastric adenocarcinoma cells.

2026-10-17T00:00:00Z

Published in Naunyn Schmiedebergs Arch Pharmacol on 17 October 2026; matched the OnCo record for ABCG2.

17 October 2026, Naunyn Schmiedebergs Arch Pharmacol.

On OnCo: ABCG2

Paper: IL-1β/IL-6 inflammatory crosstalk drives DNA methylation and histone remodeling associated with cytokine induced senescence in luminal breast cancer.

2026-10-17T00:00:00Z

Published in Inflamm Res on 17 October 2026; matched the OnCo record for DNMT3B.

17 October 2026, Inflamm Res.

On OnCo: DNMT3B

Paper: Immune Profiles and Immunotherapy Efficacy in Sinonasal Malignancies: A Scoping Review.

2026-10-17T00:00:00Z

Published in Otolaryngol Head Neck Surg on 17 October 2026; matched the OnCo record for Esthesioneuroblastoma.

17 October 2026, Otolaryngol Head Neck Surg.

On OnCo: Esthesioneuroblastoma, Sinonasal undifferentiated carcinoma (SNUC) and SWI/SNF-deficient sinonasal carcinoma, Nasal cavity and paranasal sinus cancers

Paper: Integrative transcriptomic analysis reveals tumor-adjacent mucosal remodeling in colorectal cancer.

2026-10-17T00:00:00Z

Published on 17 October 2026 after first appearing as a preprint; matched RNA sequencing & expression profiling and Single-cell & spatial profiling.

17 October 2026.

On OnCo: RNA sequencing & expression profiling, Single-cell & spatial profiling

Paper: Intravitreal methotrexate as a prophylactic strategy for proliferative vitreoretinopathy in high-risk retinal detachment.

2026-10-17T00:00:00Z

Published on 17 October 2026 after first appearing as a preprint; matched Methotrexate and CD155.

17 October 2026.

On OnCo: Methotrexate, CD155

Paper: MRI-defined parametrial venous invasion in locally advanced cervical cancer: association with pathological venous invasion, pretreatment lymph node metastasis, and survival outcomes.

2026-10-17T00:00:00Z

Published in Jpn J Radiol on 17 October 2026; matched the OnCo record for Locally advanced cervical cancer.

17 October 2026, Jpn J Radiol.

On OnCo: Locally advanced cervical cancer

Paper: Multidimensional Clinical Benefits of Cinnamon Leaf Oil Inhalation in Primary and Metastatic Brain Tumor Patients During Winter: A Randomized Controlled Trial.

2026-10-17T00:00:00Z

Published in Complement Ther Med on 17 October 2026; matched the OnCo record for Aromatherapy.

17 October 2026, Complement Ther Med.

On OnCo: Aromatherapy

Paper: Multiparametric MRI with amide proton transfer imaging for assessing stromal invasion depth of early- stage cervical cancer.

2026-10-17T00:00:00Z

Published in Magn Reson Imaging on 17 October 2026; matched the OnCo record for Early cervical cancer and fertility-sparing surgery.

17 October 2026, Magn Reson Imaging.

On OnCo: Early cervical cancer and fertility-sparing surgery

Paper: NECTIN-4 orchestrates macrophage-mediated tumor plasticity in oral squamous cell carcinoma.

2026-10-17T00:00:00Z

Published in Cell Signal on 17 October 2026; matched the OnCo record for ANGPT1.

17 October 2026, Cell Signal.

On OnCo: ANGPT1, Nectin-4

Paper: Nuclear Eccentricity as a Potential Biomarker for Tumor Biology and Survival in Glioblastoma.

2026-10-17T00:00:00Z

Published on 17 October 2026 after first appearing as a preprint; matched SET.

17 October 2026.

On OnCo: SET

Paper: Optimization of catheter placement for interstitial gynecological brachytherapy with centroidal Voronoi tessellation.

2026-10-17T00:00:00Z

Published in Brachytherapy on 17 October 2026; matched the OnCo record for Locally advanced cervical cancer.

17 October 2026, Brachytherapy.

On OnCo: Locally advanced cervical cancer

Paper: Outcomes of Allogeneic Stem Cell Transplantation in a North American Adult T Cell Leukemia/Lymphoma Cohort.

2026-10-17T00:00:00Z

Published in Transplant Cell Ther on 17 October 2026; matched the OnCo record for Adult T-cell leukaemia/lymphoma.

17 October 2026, Transplant Cell Ther.

On OnCo: Adult T-cell leukaemia/lymphoma, Allogeneic stem cell transplantation

Paper: Palliative radiotherapy for gastric cancer-related bleeding: a systematic review and meta-analysis of bleeding response and dose-response relationships.

2026-10-17T00:00:00Z

Published in Jpn J Radiol on 17 October 2026; matched the OnCo record for Palliative radiotherapy.

17 October 2026, Jpn J Radiol.

On OnCo: Palliative radiotherapy

Paper: Peripheral precocious puberty in a 4-month-old infant associated with an ESR1 variant: a case report.

2026-10-17T00:00:00Z

Published in Oxf Med Case Reports on 17 October 2026; matched the OnCo record for Letrozole.

17 October 2026, Oxf Med Case Reports.

On OnCo: Letrozole

Paper: Phosphorylation of IRS4 at YY111/112 promotes LUSC progression via PI3K/AKT pathway activation.

2026-10-17T00:00:00Z

Published in Oncogene on 17 October 2026; matched the OnCo record for IRS4.

17 October 2026, Oncogene.

On OnCo: IRS4

Paper: Protocol for eVLP-mediated CRISPR-Cas9 and prime editing in pancreatic cancer cell lines.

2026-10-17T00:00:00Z

Published in STAR Protoc on 17 October 2026; matched the OnCo record for EPHA8.

17 October 2026, STAR Protoc.

On OnCo: EPHA8

Paper: Repurposing Entrectinib and Ibrutinib as MNK/eIF4E Pathway Modulators in Ovarian Cancer.

2026-10-17T00:00:00Z

Published in Eur J Pharmacol on 17 October 2026; matched the OnCo record for Entrectinib.

17 October 2026, Eur J Pharmacol.

On OnCo: Entrectinib

Paper: Restricted mean survival time-based network meta-analysis of first-line therapies for metastatic clear cell renal cell carcinoma.

2026-10-17T00:00:00Z

Published in Urol Oncol on 17 October 2026; matched the OnCo record for Avelumab.

17 October 2026, Urol Oncol.

On OnCo: Avelumab, Cabozantinib, Ipilimumab

Paper: THINKERS-X: multisequence MRI radiomics in a mixture-of-experts model for outcome prediction and exploratory dose-scenario evaluation in lung cancer brain metastases treated with radiosurgery.

2026-10-17T00:00:00Z

Published in Clin Exp Metastasis on 17 October 2026; matched the OnCo record for Gamma Knife.

17 October 2026, Clin Exp Metastasis.

On OnCo: Gamma Knife

Paper: Tumour-proximal deep serum proteomics identifies biomarkers associated with ovarian cancer.

2026-10-17T00:00:00Z

Published in Mol Oncol on 17 October 2026; matched the OnCo record for ANK1.

17 October 2026, Mol Oncol.

On OnCo: ANK1

Paper: When response lasts: ORR4 as an On-Treatment Prognostic Marker in Mogamulizumab-Treated Mycosis Fungoides and Sézary Syndrome.

2026-10-17T00:00:00Z

Published in Br J Dermatol on 17 October 2026; matched the OnCo record for Mogamulizumab.

17 October 2026, Br J Dermatol.

On OnCo: Mogamulizumab, Sezary syndrome

Paper: [Corrigendum] Acquired resistance of pancreatic cancer cells to treatment with gemcitabine and HER‑inhibitors is accompanied by increased sensitivity to STAT3 inhibition.

2026-10-16T00:00:00Z

Published in Int J Oncol on 16 October 2026; matched the OnCo record for STAT3.

16 October 2026, Int J Oncol.

On OnCo: STAT3

Paper: [Patients with papillary craniopharyngioma successfully treated with BRAF and MEK inhibitors].

2026-10-16T00:00:00Z

Published in Lakartidningen on 16 October 2026; matched the OnCo record for Craniopharyngioma.

16 October 2026, Lakartidningen.

On OnCo: Craniopharyngioma

Paper: Disporum cantoniense suppresses non‑small cell lung cancer through AMPK/mTOR/ULK1‑mediated autophagy‑dependent apoptosis.

2026-10-16T00:00:00Z

Published in Int J Oncol on 16 October 2026; matched the OnCo record for ATG7.

16 October 2026, Int J Oncol.

On OnCo: ATG7, BAX, BCL-2

Paper: PIK3CA Mutations in Advanced or Recurrent Endometrial Cancer: An Exploratory Molecular Profiling From the Phase II MITO END-3 Study.

2026-10-16T00:00:00Z

Published in JCO Precis Oncol on 16 October 2026; matched the OnCo record for Advanced or recurrent endometrial cancer.

16 October 2026, JCO Precis Oncol.

On OnCo: Advanced or recurrent endometrial cancer, Alpelisib, ARID1A

Paper: 68Ga-Pentixafor PET/MRI for identifying corticotroph adenomas in Cushing disease: a pilot study.

2026-10-16T00:00:00Z

Published in Pituitary on 16 October 2026; matched the OnCo record for PET/MRI.

16 October 2026, Pituitary.

On OnCo: PET/MRI

Paper: A cytoplasmic cis-acting circuit confines PI3K/AKT-driven lineage plasticity in bladder cancer.

2026-10-16T00:00:00Z

Published in Cell Signal on 16 October 2026; matched the OnCo record for UBC.

16 October 2026, Cell Signal.

On OnCo: UBC

Paper: A multimodal MRI radiomics sonata for differentiating small renal masses: a two-center retrospective study.

2026-10-16T00:00:00Z

Published in Clinics (Sao Paulo) on 16 October 2026; matched the OnCo record for SRMS.

16 October 2026, Clinics (Sao Paulo).

On OnCo: SRMS

Paper: A performance evaluation of a multi-soil-layering for the treatment of an olive mill wastewater.

2026-10-16T00:00:00Z

Published in Environ Geochem Health on 16 October 2026; matched the OnCo record for Mesenchymal stem-like triple-negative breast cancer.

16 October 2026, Environ Geochem Health.

On OnCo: Mesenchymal stem-like triple-negative breast cancer

Paper: A prognostic model based on seven cell adhesion molecule-related genes to predict the prognosis of colorectal cancer.

2026-10-16T00:00:00Z

Published in Cytotechnology on 16 October 2026; matched the OnCo record for Dasatinib.

16 October 2026, Cytotechnology.

On OnCo: Dasatinib, Erlotinib, Gemcitabine, Imatinib, Lapatinib

Paper: A robust biomarker combining radiomic and CA19.9 information to predict distant relapse-free survival after radiochemotherapy in pancreatic cancer.

2026-10-16T00:00:00Z

Published in Dig Liver Dis on 16 October 2026; matched the OnCo record for Locally advanced unresectable pancreatic ductal adenocarcinoma.

16 October 2026, Dig Liver Dis.

On OnCo: Locally advanced unresectable pancreatic ductal adenocarcinoma

Paper: Active Surveillance for Intermediate-risk Prostate Cancer: Implications of AI-enabled Pattern Quantification.

2026-10-16T00:00:00Z

Published in Eur Urol Focus on 16 October 2026; matched the OnCo record for Localised prostate cancer, intermediate risk.

16 October 2026, Eur Urol Focus.

On OnCo: Localised prostate cancer, intermediate risk

Paper: Advances in neoadjuvant therapy for locally advanced head and neck squamous cell carcinoma (Review).

2026-10-16T00:00:00Z

Published in Oncol Rep on 16 October 2026; matched the OnCo record for Cetuximab.

16 October 2026, Oncol Rep.

On OnCo: Cetuximab, Cytotoxic chemotherapy, Fluorouracil, Head and neck squamous cell carcinoma, Monoclonal antibodies

Paper: AmpliconSuite: an end-to-end workflow for analyzing focal amplifications in cancer genomes.

2026-10-16T00:00:00Z

Published on 16 October 2026 after first appearing as a preprint; matched Whole-exome & whole-genome sequencing.

16 October 2026.

On OnCo: Whole-exome & whole-genome sequencing

Paper: An evaluation of sacituzumab tirumotecan for the treatment of NSCLC.

2026-10-16T00:00:00Z

Published in Expert Opin Biol Ther on 16 October 2026; matched the OnCo record for Sacituzumab tirumotecan.

16 October 2026, Expert Opin Biol Ther.

On OnCo: Sacituzumab tirumotecan

Paper: An Integrative Multi-Omic Biomarker Panel Distinguishes Hepatocellular Carcinoma From Chronic Liver Disease in HBV-Predominant Populations.

2026-10-16T00:00:00Z

Published in Hepatol Res on 16 October 2026; matched the OnCo record for Diethylstilbestrol.

16 October 2026, Hepatol Res.

On OnCo: Diethylstilbestrol

Paper: Apolipoprotein A1 attenuates epirubicin-induced cardiotoxicity with GPX4-linked ferroptosis-defense modulation.

2026-10-16T00:00:00Z

Published in Apoptosis on 16 October 2026; matched the OnCo record for Epirubicin.

16 October 2026, Apoptosis.

On OnCo: Epirubicin, KLF4

Paper: ASO Visual Abstract: Does Additional Margin Excision During Pegulicianine Fluorescence-Guided Surgery (pFGS) Affect Patient Breast Satisfaction?

2026-10-16T00:00:00Z

Published in Ann Surg Oncol on 16 October 2026; matched the OnCo record for Pegulicianine.

16 October 2026, Ann Surg Oncol.

On OnCo: Pegulicianine

Paper: Associations of Antibodies Against Several Infections With Alzheimer Disease Neuropathology: A Prospective Cohort Study Analysis.

2026-10-16T00:00:00Z

Published on 16 October 2026 after first appearing as a preprint; matched CCDC6 and APOE.

16 October 2026.

On OnCo: CCDC6, APOE

Paper: Author response to the Letter to the Editor: "Model informed precision dosing for most accurate busulfan therapeutic drug monitoring".

2026-10-16T00:00:00Z

Published in J Oncol Pharm Pract on 16 October 2026; matched the OnCo record for Busulfan.

16 October 2026, J Oncol Pharm Pract.

On OnCo: Busulfan

Paper: Bibliometric mapping of research trends and publication growth in cancer sonodynamic therapy from 2001 to 2025.

2026-10-16T00:00:00Z

Published on 16 October 2026 after first appearing as a preprint; matched Sonodynamic therapy.

16 October 2026.

On OnCo: Sonodynamic therapy

Paper: Cardiovascular Toxicities Associated With Immune Checkpoint Inhibitors: Clinical Phenotypes, Mechanisms, Diagnosis, and Management-A Narrative Review.

2026-10-16T00:00:00Z

Published in Crit Rev Oncol Hematol on 16 October 2026; matched the OnCo record for Alemtuzumab.

16 October 2026, Crit Rev Oncol Hematol.

On OnCo: Alemtuzumab

Paper: Cell-free DNA fragmentomics and epigenomic profiling in hematologic malignancies: current evidence, translational limitations, and future directions.

2026-10-16T00:00:00Z

Published in Transl Oncol on 16 October 2026; matched the OnCo record for cfDNA fragmentomics.

16 October 2026, Transl Oncol.

On OnCo: cfDNA fragmentomics

Paper: CellDiffusion: Enhancing scRNA-seq data integration with accurate inference of cell-cell association.

2026-10-16T00:00:00Z

Published on 16 October 2026 after first appearing as a preprint; matched Single-cell & spatial profiling.

16 October 2026.

On OnCo: Single-cell & spatial profiling

Paper: Chimeric Antigen Receptor T-Cell Therapy in T Cell/Histiocyte-Rich Large B-Cell Lymphoma: A Systematic Review and Meta-Analysis.

2026-10-16T00:00:00Z

Published in Eur J Haematol on 16 October 2026; matched the OnCo record for T-cell/histiocyte-rich large B-cell lymphoma.

16 October 2026, Eur J Haematol.

On OnCo: T-cell/histiocyte-rich large B-cell lymphoma

Paper: Clinical characteristics and outcome of a cohort of CLL patients with BTK T474 gatekeeper mutation.

2026-10-16T00:00:00Z

Published in Blood Adv on 16 October 2026; matched the OnCo record for Acalabrutinib.

16 October 2026, Blood Adv.

On OnCo: Acalabrutinib, Relapsed or refractory chronic lymphocytic leukaemia, Nemtabrutinib, Pirtobrutinib, SF3B1

Paper: Cobimetinib + Vemurafenib in Patients With BRAF V600E-Mutant Papillary Thyroid and Biliary Tract Cancers: Results From the TAPUR Study.

2026-10-16T00:00:00Z

Published in JCO Precis Oncol on 16 October 2026; matched the OnCo record for Cobimetinib.

16 October 2026, JCO Precis Oncol.

On OnCo: Cobimetinib, Vemurafenib

Paper: Computational deconvolution of drug sensitivity via single-cell-to-bulk transcriptome mapping.

2026-10-16T00:00:00Z

Published in PLoS Comput Biol on 16 October 2026; matched the OnCo record for Midostaurin.

16 October 2026, PLoS Comput Biol.

On OnCo: Midostaurin

Paper: Current perspectives in the pharmacological combination treatment for low-grade serous ovarian cancer.

2026-10-16T00:00:00Z

Published in Expert Opin Pharmacother on 16 October 2026; matched the OnCo record for Avutometinib + defactinib.

16 October 2026, Expert Opin Pharmacother.

On OnCo: Avutometinib + defactinib, Low-grade serous ovarian cancer

Paper: Current State of Adjuvant Hormone Therapy in Prostate Cancer and in the Management of Pelvic Nodal Recurrence: A Narrative Review.

2026-10-16T00:00:00Z

Published on 16 October 2026 after first appearing as a preprint; matched Androgen deprivation & AR pathway inhibitors and State.

16 October 2026.

On OnCo: Androgen deprivation & AR pathway inhibitors, State

Paper: Decision regret after partial nephrectomy for benign small renal masses: The importance of preoperative counselling.

2026-10-16T00:00:00Z

Published in BJUI Compass on 16 October 2026; matched the OnCo record for SRMS.

16 October 2026, BJUI Compass.

On OnCo: SRMS

Paper: Dielectrophoresis-Assisted PVDF/DES/Au NP-Based Microfluidic ECL Biosensor for In Situ Detection of Extracellular Vesicles.

2026-10-16T00:00:00Z

Published in ACS Sens on 16 October 2026; matched the OnCo record for Diethylstilbestrol.

16 October 2026, ACS Sens.

On OnCo: Diethylstilbestrol

Paper: Dietary anthocyanins as multifunctional bioactives targeting obesity across experimental and clinical models.

2026-10-16T00:00:00Z

Published in Food Funct on 16 October 2026; matched the OnCo record for PRDM16.

16 October 2026, Food Funct.

On OnCo: PRDM16

Paper: Dynamic remodeling of the KRAS interactome by direct RAS inhibitors with distinct mechanism of action reveals convergent responses.

2026-10-16T00:00:00Z

Published in Oncogene on 16 October 2026; matched the OnCo record for AFDN.

16 October 2026, Oncogene.

On OnCo: AFDN

Paper: Epigallocatechin gallate and thermal cycling‑stimulation synergistically promote apoptosis in A549 cells via endoplasmic reticulum stress‑induced calcium ion dysregulation and oxidative stress.

2026-10-16T00:00:00Z

Published in Mol Med Rep on 16 October 2026; matched the OnCo record for Proteasome.

16 October 2026, Mol Med Rep.

On OnCo: Proteasome

Paper: Exposure to hypothyroid serum alters expression of oncogenes and tumor suppressors in preneoplastic breast cells.

2026-10-16T00:00:00Z

Published in Endokrynol Pol on 16 October 2026; matched the OnCo record for AGR2.

16 October 2026, Endokrynol Pol.

On OnCo: AGR2, THRB

Paper: Flow cytometric assessment of T-cell receptor β-chain constant region 1/2 skewing as a surrogate marker for clonality in human T-cell leukaemia virus type-1-infected cells.

2026-10-16T00:00:00Z

Published in Br J Haematol on 16 October 2026; matched the OnCo record for Adult T-cell leukaemia/lymphoma.

16 October 2026, Br J Haematol.

On OnCo: Adult T-cell leukaemia/lymphoma

Paper: Glycyrrhizic acid attenuates corneal inflammation and pathological angiogenesis through FAK/PI3K/AKT signaling.

2026-10-16T00:00:00Z

Published in Mol Med Rep on 16 October 2026; matched the OnCo record for BAX.

16 October 2026, Mol Med Rep.

On OnCo: BAX, BCL-2, CCND1, FAK

Paper: Harnessing the ubiquitin-proteasome system: advances and challenges of PROTACs in breast cancer.

2026-10-16T00:00:00Z

Published in Mol Biol Rep on 16 October 2026; matched the OnCo record for Vepdegestrant.

16 October 2026, Mol Biol Rep.

On OnCo: Vepdegestrant

Paper: HDAC8 Assistant: a QSAR-guided molecular generation platform for de novo design and virtual screening of HDAC8 inhibitors.

2026-10-16T00:00:00Z

Published in SAR QSAR Environ Res on 16 October 2026; matched the OnCo record for HDAC8.

16 October 2026, SAR QSAR Environ Res.

On OnCo: HDAC8

Paper: Hematologic Malignancies With RUNX1::ZFPM2 Translocation: A Case Report and Literature Review.

2026-10-16T00:00:00Z

Published in EJHaem on 16 October 2026; matched the OnCo record for RUNX1T1.

16 October 2026, EJHaem.

On OnCo: RUNX1T1, ZFPM2

Paper: Higher ARNT expression is associated with the sparsely granulated phenotype in somatotroph pituitary adenomas: An immunohistochemical study.

2026-10-16T00:00:00Z

Published in Pituitary on 16 October 2026; matched the OnCo record for ARNT.

16 October 2026, Pituitary.

On OnCo: ARNT

Paper: HPV vaccination coverage and barriers for people with disability: A scoping review.

2026-10-16T00:00:00Z

Published in Hum Vaccin Immunother on 16 October 2026; matched the OnCo record for HPV & HBV vaccination.

16 October 2026, Hum Vaccin Immunother.

On OnCo: HPV & HBV vaccination

Paper: Hyperprolactinemia and corneal ectasia risk: A tomographic and densitometric analysis in prolactinoma patients.

2026-10-16T00:00:00Z

Published in Indian J Ophthalmol on 16 October 2026; matched the OnCo record for Lactotroph pituitary neuroendocrine tumour.

16 October 2026, Indian J Ophthalmol.

On OnCo: Lactotroph pituitary neuroendocrine tumour

Paper: Identification of Macrophage Polarization-Related Biomarkers in Multiple Myeloma Using Integrated Bioinformatics.

2026-10-16T00:00:00Z

Published in J Vis Exp on 16 October 2026; matched the OnCo record for IL2RG.

16 October 2026, J Vis Exp.

On OnCo: IL2RG

Paper: Immunosenescence markers as predictors of cutaneous keratinocyte carcinoma risk in heart transplant recipients: a prospective pilot study of 30 patients.

2026-10-16T00:00:00Z

Published in Actas Dermosifiliogr on 16 October 2026; matched the OnCo record for CD57.

16 October 2026, Actas Dermosifiliogr.

On OnCo: CD57

Paper: Incidence and Risk Factors of Treatment-Emergent Eczematous Reactions in Patients with Psoriasis Treated with Biologics: A Systematic Review and Meta-Analysis.

2026-10-16T00:00:00Z

Published in BioDrugs on 16 October 2026; matched the OnCo record for TYK2.

16 October 2026, BioDrugs.

On OnCo: TYK2

Paper: Insights into the degradation behaviour of tucatinib under stress conditions using liquid chromatography high resolution tandem mass spectrometry.

2026-10-16T00:00:00Z

Published in Anal Methods on 16 October 2026; matched the OnCo record for Tucatinib.

16 October 2026, Anal Methods.

On OnCo: Tucatinib

Paper: Isorhapontigenin alleviates sepsis-induced acute lung injury by targeting the RAF1-ERK1/2-CXCL10 axis to inhibit CXCR3+ neutrophil recruitment.

2026-10-16T00:00:00Z

Published in Eur J Pharmacol on 16 October 2026; matched the OnCo record for CRAF.

16 October 2026, Eur J Pharmacol.

On OnCo: CRAF

Paper: ITF2357 exerts anti‑tumor activity in colorectal cancer via the miR‑1938/ADAM12 axis.

2026-10-16T00:00:00Z

Published in Mol Biol Rep on 16 October 2026; matched the OnCo record for Givinostat.

16 October 2026, Mol Biol Rep.

On OnCo: Givinostat

Paper: Large Carinal Chondrosarcoma: Resection of the Main Carina, Distal Trachea, and Orifices of the Mainstem Bronchi and Construction of a New Carina.

2026-10-16T00:00:00Z

Published in Am J Case Rep on 16 October 2026; matched the OnCo record for Chondrosarcoma.

16 October 2026, Am J Case Rep.

On OnCo: Chondrosarcoma

Paper: Light- and ROS-responsive nanomicelles enable targeted combination photothermal molecular therapy in melanoma cells and spheroids.

2026-10-16T00:00:00Z

Published in Nanoscale on 16 October 2026; matched the OnCo record for PSMC4.

16 October 2026, Nanoscale.

On OnCo: PSMC4, RPS6

Paper: LncRNA GAS5 Restrains Hepatocellular Carcinoma by Targeting the miR-18a-5p-CADM2 Axis.

2026-10-16T00:00:00Z

Published in Biochem Genet on 16 October 2026; matched the OnCo record for CADM2.

16 October 2026, Biochem Genet.

On OnCo: CADM2

Paper: Machine Learning Quantifies Within-Subject Facial Change in Acromegaly.

2026-10-16T00:00:00Z

Published in Eur J Endocrinol on 16 October 2026; matched the OnCo record for Somatotroph pituitary neuroendocrine tumour.

16 October 2026, Eur J Endocrinol.

On OnCo: Somatotroph pituitary neuroendocrine tumour

Paper: Medium-Frequency Electrotherapy-Driven Remodeling of Tumor Biology and Overcoming Treatment Resistance: Molecular Mechanisms and Clinical Integration.

2026-10-16T00:00:00Z

Published in J Mol Cell Biol on 16 October 2026; matched the OnCo record for Tumour treating fields.

16 October 2026, J Mol Cell Biol.

On OnCo: Tumour treating fields

Paper: Mohs micrographic surgery for dermatofibrosarcoma protuberans: our experience using frozen sections and a literature review.

2026-10-16T00:00:00Z

Published in Actas Dermosifiliogr on 16 October 2026; matched the OnCo record for Dermatofibrosarcoma protuberans.

16 October 2026, Actas Dermosifiliogr.

On OnCo: Dermatofibrosarcoma protuberans

Paper: Monomorphic Epitheliotropic Intestinal T-Cell Lymphoma: Clinicopathologic and Genetic Analysis of a Large Chinese Cohort.

2026-10-16T00:00:00Z

Published in Am J Surg Pathol on 16 October 2026; matched the OnCo record for CDKN2B.

16 October 2026, Am J Surg Pathol.

On OnCo: CDKN2B, JAK3, Monomorphic epitheliotropic intestinal T-cell lymphoma, SDHD, STK11, TP63, TSC2

Paper: Multimodal imaging features of nuclear protein in testis carcinoma of the submandibular gland: a case report.

2026-10-16T00:00:00Z

Published in J Med Case Rep on 16 October 2026; matched the OnCo record for NUT carcinoma.

16 October 2026, J Med Case Rep.

On OnCo: NUT carcinoma, MRI, PET, PET/CT

Paper: Navigating the landscape of targeted therapies for renal cell carcinoma in the era of precision medicine (Review).

2026-10-16T00:00:00Z

Published in Mol Med Rep on 16 October 2026; matched the OnCo record for Axitinib.

16 October 2026, Mol Med Rep.

On OnCo: Axitinib, BRCA1 / BRCA2, Ipilimumab, Lenvatinib, Nivolumab, PBRM1, Pembrolizumab, Renal cell carcinoma, Sirolimus, SMARCA4

Paper: Neoadjuvant Chemo-Immunotherapy Yields Survival Comparable to Upfront Surgery in Metaplastic Breast Cancer: A National Cancer Database Analysis.

2026-10-16T00:00:00Z

Published in Ann Surg Oncol on 16 October 2026; matched the OnCo record for Metaplastic breast carcinoma.

16 October 2026, Ann Surg Oncol.

On OnCo: Metaplastic breast carcinoma

Paper: Oncolytic virotherapy for cancer: biological mechanisms, clinical advances, and future perspectives.

2026-10-16T00:00:00Z

Published in Clin Exp Med on 16 October 2026; matched the OnCo record for Talimogene laherparepvec.

16 October 2026, Clin Exp Med.

On OnCo: Talimogene laherparepvec

Paper: Optimisation and mechanistic characterization of a selective benzoxazine-based MAP4K4 inhibitor in pancreatic cancer cells.

2026-10-16T00:00:00Z

Published in J Enzyme Inhib Med Chem on 16 October 2026; matched the OnCo record for AIMP2.

16 October 2026, J Enzyme Inhib Med Chem.

On OnCo: AIMP2

Paper: PA4933 Mediates Dual Regulation of Oxidative Resistance and Virulence in Pseudomonas aeruginosa Pulmonary Infection.

2026-10-16T00:00:00Z

Published in Microb Pathog on 16 October 2026; matched the OnCo record for Primary effusion lymphoma.

16 October 2026, Microb Pathog.

On OnCo: Primary effusion lymphoma

Paper: PABPC1 dictates castration sensitivity in prostate cancer via orchestrating ferroptosis resistance and CD8(+) T-cell dysfunction.

2026-10-16T00:00:00Z

Published in Cell Death Differ on 16 October 2026; matched the OnCo record for EIF4A1.

16 October 2026, Cell Death Differ.

On OnCo: EIF4A1, Ixazomib, PABPC1

Paper: Pancreatic Invasion in Distal Cholangiocarcinoma Is a Poor Prognostic Factor: A New Approach Integrating Tumor Depth of Invasion.

2026-10-16T00:00:00Z

Published in ANZ J Surg on 16 October 2026; matched the OnCo record for Extrahepatic cholangiocarcinoma.

16 October 2026, ANZ J Surg.

On OnCo: Extrahepatic cholangiocarcinoma

Paper: Patient acceptance and experience with contrast-enhanced mammography in women with a personal history of breast cancer: findings from the COMBO trial.

2026-10-16T00:00:00Z

Published in Insights Imaging on 16 October 2026; matched the OnCo record for Contrast-enhanced mammography.

16 October 2026, Insights Imaging.

On OnCo: Contrast-enhanced mammography

Paper: PBRM1 knockdown is associated with NRF2‑dependent ALDOA upregulation and metabolic reprogramming in HCCC‑9810 intrahepatic cholangiocarcinoma cells.

2026-10-16T00:00:00Z

Published in Oncol Rep on 16 October 2026; matched the OnCo record for Ki-67.

16 October 2026, Oncol Rep.

On OnCo: Ki-67, PBRM1

Paper: Pediatric prolactinoma-associated pituitary apoplexy presenting with acute visual loss: a case report, literature review, and management strategy.

2026-10-16T00:00:00Z

Published in J Pediatr Endocrinol Metab on 16 October 2026; matched the OnCo record for Cabergoline.

16 October 2026, J Pediatr Endocrinol Metab.

On OnCo: Cabergoline, Lactotroph pituitary neuroendocrine tumour

Paper: Persistent chemotherapy-induced alopecia: a scoping review.

2026-10-16T00:00:00Z

Published in Curr Opin Support Palliat Care on 16 October 2026; matched the OnCo record for Scalp cooling.

16 October 2026, Curr Opin Support Palliat Care.

On OnCo: Scalp cooling

Paper: Pharmacokinetics and efficacy of tank-water-administered dabrafenib, a BRAF inhibitor, in a zebrafish model of melanoma.

2026-10-16T00:00:00Z

Published in Dis Model Mech on 16 October 2026; matched the OnCo record for BRAF V600-mutant melanoma.

16 October 2026, Dis Model Mech.

On OnCo: BRAF V600-mutant melanoma

Paper: Plasma-Derived Genomic Instability Status and Rucaparib Outcomes in Metastatic Castration-Resistant Prostate Cancer: TRITON2.

2026-10-16T00:00:00Z

Published in JCO Precis Oncol on 16 October 2026; matched the OnCo record for HRD & BRCA testing.

16 October 2026, JCO Precis Oncol.

On OnCo: HRD & BRCA testing, PALB2, Rucaparib

Paper: Platelet Dysfunction in Liver and Kidney Disease.

2026-10-16T00:00:00Z

Published in Hematol Oncol Clin North Am on 16 October 2026; matched the OnCo record for VWF.

16 October 2026, Hematol Oncol Clin North Am.

On OnCo: VWF

Paper: Practical Review of Role and Usage of Corticosteroids in Modern Neuro-Oncology Care.

2026-10-16T00:00:00Z

Published in Neurol Clin Pract on 16 October 2026; matched the OnCo record for Anti-angiogenic therapy.

16 October 2026, Neurol Clin Pract.

On OnCo: Anti-angiogenic therapy, Bevacizumab, Bevacizumab

Paper: Prediction residuals in spatial transcriptomics reveal microenvironmental heterogeneity in cancer.

2026-10-16T00:00:00Z

Published in Comput Biol Med on 16 October 2026; matched the OnCo record for Pathology & radiology foundation models.

16 October 2026, Comput Biol Med.

On OnCo: Pathology & radiology foundation models

Paper: Prognostic Significance of Contrast Enhancement in Newly Diagnosed Grade 2 IDH-mutant Glioma.

2026-10-16T00:00:00Z

Published in Neuro Oncol on 16 October 2026; matched the OnCo record for Vorasidenib.

16 October 2026, Neuro Oncol.

On OnCo: Vorasidenib

Paper: Project international Delphi consensus recommendations for perioperative management of inguinal lymphadenectomy in cancer patients.

2026-10-16T00:00:00Z

Published in Urol Oncol on 16 October 2026; matched the OnCo record for Penile cancer.

16 October 2026, Urol Oncol.

On OnCo: Penile cancer, Vulvar cancer

Paper: Prospective phase I study of nivolumab to promote graft-versus-tumour in relapsed or refractory haematological malignancy post allogeneic haematopoietic stem cell transplantation.

2026-10-16T00:00:00Z

Published in Br J Haematol on 16 October 2026; matched the OnCo record for Acute lymphoblastic leukaemia.

16 October 2026, Br J Haematol.

On OnCo: Acute lymphoblastic leukaemia

Paper: Prospectively collected functional vs. self-reported frailty measures and postoperative outcomes after radical cystectomy in older adults with bladder cancer.

2026-10-16T00:00:00Z

Published in Urol Oncol on 16 October 2026; matched the OnCo record for Geriatric assessment.

16 October 2026, Urol Oncol.

On OnCo: Geriatric assessment

Paper: Radiotherapy combined with serplulimab, and chemotherapy as first-line treatment for metastatic pancreatic adenocarcinoma: a multicenter, single-arm, phase II trial.

2026-10-16T00:00:00Z

Published in Clin Cancer Res on 16 October 2026; matched the OnCo record for Serplulimab.

16 October 2026, Clin Cancer Res.

On OnCo: Serplulimab

Paper: Rapid-Onset Opioid-Induced Neurotoxicity During Morphine Therapy.

2026-10-16T00:00:00Z

Published in Am J Hosp Palliat Care on 16 October 2026; matched the OnCo record for Cancer pain management.

16 October 2026, Am J Hosp Palliat Care.

On OnCo: Cancer pain management

Paper: Research progress of SPP1 in cancer regulation: Tumorigenesis, metastasis, tumor microenvironment, immunity and therapeutic targets (Review).

2026-10-16T00:00:00Z

Published in Int J Oncol on 16 October 2026; matched the OnCo record for CD44.

16 October 2026, Int J Oncol.

On OnCo: CD44

Paper: Response to De Giorgi et al., "Surgical delay in early-stage vulvar melanoma: caution in defining a causal threshold."

2026-10-16T00:00:00Z

Published in J Am Acad Dermatol on 16 October 2026; matched the OnCo record for Vulvar melanoma.

16 October 2026, J Am Acad Dermatol.

On OnCo: Vulvar melanoma

Paper: Reversible atrioventricular block associated with transdermal fentanyl use: a paediatric case with non-Hodgkin lymphoma.

2026-10-16T00:00:00Z

Published in Cardiol Young on 16 October 2026; matched the OnCo record for Fentanyl.

16 October 2026, Cardiol Young.

On OnCo: Fentanyl

Paper: Revisiting the impact of synthetic ORF sequences on engineered LINE-1 retrotransposition.

2026-10-16T00:00:00Z

Published on 16 October 2026 after first appearing as a preprint; matched NCKIPSD.

16 October 2026.

On OnCo: NCKIPSD

Paper: ROCK2 regulates a stress-responsive transcriptional state and calcium signaling in renal cell carcinoma.

2026-10-16T00:00:00Z

Published in Mol Cell Biochem on 16 October 2026; matched the OnCo record for CREB1.

16 October 2026, Mol Cell Biochem.

On OnCo: CREB1

Paper: Self-assembled floxuridine prodrug nanovesicles for synergistic drug delivery and gene silencing.

2026-10-16T00:00:00Z

Published in Chem Commun (Camb) on 16 October 2026; matched the OnCo record for Floxuridine.

16 October 2026, Chem Commun (Camb).

On OnCo: Floxuridine

Paper: Sex Hormone Estrone Sulfate Serendipitously Downregulates Intercellular Tunneling Nanotube Conduits, EMT, and Migration in Breast and Pancreatic Cancer Cells.

2026-10-16T00:00:00Z

Published on 16 October 2026 after first appearing as a preprint; matched HER2, Estrogen receptor and JUN.

16 October 2026.

On OnCo: HER2, Estrogen receptor, JUN, EGF, FOS, FOSB

Paper: Six3 promoting the migration and neural differentiation of BMSCs via Btg2‑mediated Akt signaling pathway activation: A therapeutic strategy for stroke.

2026-10-16T00:00:00Z

Published in Int J Mol Med on 16 October 2026; matched the OnCo record for BTG2.

16 October 2026, Int J Mol Med.

On OnCo: BTG2

Paper: SOX10 Expression in Primary Salivary Gland Tumors: A Meta-Analysis.

2026-10-16T00:00:00Z

Published in Head Neck Pathol on 16 October 2026; matched the OnCo record for BioEmu.

16 October 2026, Head Neck Pathol.

On OnCo: BioEmu

Paper: Spatial localization patterns in MRI-negative Cushing disease: a comparative pituitary heat map analysis.

2026-10-16T00:00:00Z

Published in J Neurosurg on 16 October 2026; matched the OnCo record for CD96.

16 October 2026, J Neurosurg.

On OnCo: CD96

Paper: STAT3 operates as an inflammation-dependent transcriptional switch in antiviral NK cells.

2026-10-16T00:00:00Z

Published in Sci Immunol on 16 October 2026; matched the OnCo record for MYB.

16 October 2026, Sci Immunol.

On OnCo: MYB, MYBL1, PRDM1

Paper: Synthetic Notch CD123 and CLL1 chimeric antigen receptor T-cells (CAR-T) target acute myeloid leukemia and reduce off-tumor effects associated with CLL1 CAR-T cells.

2026-10-16T00:00:00Z

Published in Mol Biomed on 16 October 2026; matched the OnCo record for CD123.

16 October 2026, Mol Biomed.

On OnCo: CD123

Paper: Targeting of Immune Cells by Human Adenoviruses: CD46 Receptor Density Influences Entry of Chimaeric Ad5F35 into Natural Killer Cells.

2026-10-16T00:00:00Z

Published on 16 October 2026 after first appearing as a preprint; matched TNFRSF10B.

16 October 2026.

On OnCo: TNFRSF10B

Paper: The allogeneic eDN70(-) CAR-T Cells Without TCR or MHC Editing Exhibit Enhanced Persistence and Function.

2026-10-16T00:00:00Z

Published in Mol Ther on 16 October 2026; matched the OnCo record for Allogeneic (off-the-shelf) cell therapy.

16 October 2026, Mol Ther.

On OnCo: Allogeneic (off-the-shelf) cell therapy, CD70

Paper: The molecular heterogeneity and clinical impact of genomic driver alterations in prostate cancer.

2026-10-16T00:00:00Z

Published in Nat Commun on 16 October 2026; matched the OnCo record for MDM4.

16 October 2026, Nat Commun.

On OnCo: MDM4

Paper: The moonlighting functions of SEC13 in nonsense-mediated mRNA decay and the regulation of ER stress.

2026-10-16T00:00:00Z

Published on 16 October 2026 after first appearing as a preprint; matched RNA sequencing & expression profiling and Single-cell & spatial profiling.

16 October 2026.

On OnCo: RNA sequencing & expression profiling, Single-cell & spatial profiling

Paper: The prognostic impact of CEBPA mutation in acute myeloid leukemia patients undergoing allogeneic hematopoietic stem cell transplantation.

2026-10-16T00:00:00Z

Published in Bone Marrow Transplant on 16 October 2026; matched the OnCo record for GATA2.

16 October 2026, Bone Marrow Transplant.

On OnCo: GATA2

Paper: TONSL/TONSOKU binding to histone H3.1 is required for DNA repair.

2026-10-16T00:00:00Z

Published in Sci Adv on 16 October 2026; matched the OnCo record for Histone H3.3.

16 October 2026, Sci Adv.

On OnCo: Histone H3.3, H3-3B, H3C2, H3C4, TPR

Paper: Trans-vaccenic acid reduces HT-29 colorectal cancer cell viability and is associated with changes in apoptosis-, lipid metabolism-, and survival-related gene and candidate miRNA expression.

2026-10-16T00:00:00Z

Published in Mol Biol Rep on 16 October 2026; matched the OnCo record for CASP8.

16 October 2026, Mol Biol Rep.

On OnCo: CASP8

Paper: Unilateral vs Bilateral Hippocampal Avoidance During WBRT With Memantine for Brain Metastases: A Randomized Single-Blind Phase 2 Clinical Trial.

2026-10-16T00:00:00Z

Published in Neuro Oncol on 16 October 2026; matched the OnCo record for Memantine.

16 October 2026, Neuro Oncol.

On OnCo: Memantine

Paper: Uterine leiomyomas in HLRCC: a scoping review of presentation, histopathology, treatment patterns, and reproductive implications.

2026-10-16T00:00:00Z

Published in Eur J Hum Genet on 16 October 2026; matched the OnCo record for Fumarate hydratase-deficient renal cell carcinoma.

16 October 2026, Eur J Hum Genet.

On OnCo: Fumarate hydratase-deficient renal cell carcinoma, FH

Paper: Virilizing Juvenile Granulosa Cell Tumor in a Prepubertal Girl with Bilateral Inguinal Hernias: A Case Report.

2026-10-16T00:00:00Z

Published in J Pediatr Adolesc Gynecol on 16 October 2026; matched the OnCo record for MUC16.

16 October 2026, J Pediatr Adolesc Gynecol.

On OnCo: MUC16, Serum tumour markers: proper use and misuse

Paper: Whole Genome Sequencing-based tumor-informed circulating tumor DNA monitoring for early detection of recurrence in patients with solid tumors.

2026-10-16T00:00:00Z

Published in Oncologist on 16 October 2026; matched the OnCo record for Signatera.

16 October 2026, Oncologist.

On OnCo: Signatera

Paper: Whole-Exome and Whole-Genome Sequencing Identifies Driver CTNNB1 Mutations in Ossifying Renal Tumor of Infancy.

2026-10-16T00:00:00Z

Published in Am J Surg Pathol on 16 October 2026; matched the OnCo record for AXIN1.

16 October 2026, Am J Surg Pathol.

On OnCo: AXIN1, AXIN2, BMPR1A, ETV6, PAX8

Paper: WNK1 links ionic signals to microtubule dynamics to control pyrin inflammasome assembly.

2026-10-16T00:00:00Z

Published in Sci Adv on 16 October 2026; matched the OnCo record for WNK1.

16 October 2026, Sci Adv.

On OnCo: WNK1

Paper: ΔNp63α‑mediated regulation of tumor‑associated genes and pathways in hepatocellular carcinoma progression.

2026-10-16T00:00:00Z

Published in Mol Med Rep on 16 October 2026; matched the OnCo record for CTCF.

16 October 2026, Mol Med Rep.

On OnCo: CTCF

Paper: Addendum: Aberrant epithelial GREM1 expression initiates colonic tumorigenesis from cells outside the stem cell niche.

2026-10-09T00:00:00Z

Published in Nat Med on 9 October 2026; matched the OnCo record for GREM1.

9 October 2026, Nat Med.

On OnCo: GREM1

Approval: FDA approves pirtobrutinib for previously untreated chronic lymphocytic leukemia or small lymphocytic lymphoma

2026-10-02T00:00:00Z

On October 2, 2026, the Food and Drug Administration approved pirtobrutinib (Jaypirca, Eli Lilly and Company) for adult patients with previously untreated chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) with no known 17p deletion.

2 October 2026, FDA.

On OnCo: Pirtobrutinib, Non-Hodgkin lymphoma, Adult T-cell leukaemia/lymphoma, Leukaemia

Paper: [Analysis of clinical characteristics and prognosis of non-rhabdomyosarcoma soft tissue sarcomas in 72 children].

2026-10-15T00:00:00Z

Published in Zhonghua Er Ke Za Zhi on 15 October 2026; matched the OnCo record for Synovial sarcoma.

15 October 2026, Zhonghua Er Ke Za Zhi.

On OnCo: Synovial sarcoma

Paper: [Clinical analysis of 21 children with Xp11.2 translocation renal cell carcinoma].

2026-10-15T00:00:00Z

Published in Zhonghua Er Ke Za Zhi on 15 October 2026; matched the OnCo record for TFE3-rearranged (translocation) renal cell carcinoma.

15 October 2026, Zhonghua Er Ke Za Zhi.

On OnCo: TFE3-rearranged (translocation) renal cell carcinoma

Paper: [Clinical analysis of modified Chinese Children Leukemia Group-Acute Myeloid Leukemia 2019 regimen in treating pediatric acute myeloid leukemia].

2026-10-15T00:00:00Z

Published in Zhonghua Er Ke Za Zhi on 15 October 2026; matched the OnCo record for Acute promyelocytic leukaemia.

15 October 2026, Zhonghua Er Ke Za Zhi.

On OnCo: Acute promyelocytic leukaemia, Cladribine

Paper: [Melanocytomas : Intermediate melanocytic neoplasms with distinct morphology and molecular background].

2026-10-15T00:00:00Z

Published in Pathologie (Heidelb) on 15 October 2026; matched the OnCo record for BIM.

15 October 2026, Pathologie (Heidelb).

On OnCo: BIM, MEK1/2

Paper: [Nonimmunological systemic therapies in head and neck cancer : Cytotoxic, targeted, EGFR-directed, and supportive approaches at ASCO 2026].

2026-10-15T00:00:00Z

Published in HNO on 15 October 2026; matched the OnCo record for Amivantamab.

15 October 2026, HNO.

On OnCo: Amivantamab, Nimotuzumab

Paper: [Pathogenesis and treatment advances of CBFA2T3::GLIS2 fusion gene-driven acute megakaryoblastic leukemia].

2026-10-15T00:00:00Z

Published in Zhonghua Er Ke Za Zhi on 15 October 2026; matched the OnCo record for CBFA2T3.

15 October 2026, Zhonghua Er Ke Za Zhi.

On OnCo: CBFA2T3

Paper: [Recommendations of the Groupe Francophone des Myélodysplasies (GFM) - Diagnostic approach and management of myelodysplastic syndromes, chronic myelomonocytic leukemias, and VEXAS syndrome].

2026-10-15T00:00:00Z

Published in Bull Cancer on 15 October 2026; matched the OnCo record for Chronic myelomonocytic leukaemia and MDS/MPN overlap neoplasms.

15 October 2026, Bull Cancer.

On OnCo: Chronic myelomonocytic leukaemia and MDS/MPN overlap neoplasms, Imetelstat, Luspatercept

Paper: EZH2 mutation status predicts inferior outcomes after bendamustine-based immunochemotherapy in frontline follicular lymphoma: A GELTAMO multicenter validation study.

2026-10-15T00:00:00Z

Published in Hemasphere on 15 October 2026; matched the OnCo record for Bendamustine.

15 October 2026, Hemasphere.

On OnCo: Bendamustine

Paper: 2-Azabicyclo[3.2.1]octane-based ALK inhibitors inspired by aconitine scaffold remodeling: design, synthesis, and biological evaluation.

2026-10-15T00:00:00Z

Published in Bioorg Chem on 15 October 2026; matched the OnCo record for Ceritinib.

15 October 2026, Bioorg Chem.

On OnCo: Ceritinib

Paper: A chemical-genetic system for calreticulin exposure on cancer cells reveals immune-dependent antitumor effects.

2026-10-15T00:00:00Z

Published in Cell Death Differ on 15 October 2026; matched the OnCo record for POLD1.

15 October 2026, Cell Death Differ.

On OnCo: POLD1

Paper: A combined genetic and bioinformatic analysis implicates the CDKN1A rs1059234 variant in differentiated thyroid carcinoma susceptibility.

2026-10-15T00:00:00Z

Published in Arch Endocrinol Metab on 15 October 2026; matched the OnCo record for CDKN1B.

15 October 2026, Arch Endocrinol Metab.

On OnCo: CDKN1B

Paper: A Genetic Risk Approach to Differential Diagnosis of Type 1 Diabetes and Risk Stratification in the Spanish Population.

2026-10-15T00:00:00Z

Published in Eur J Endocrinol on 15 October 2026; matched the OnCo record for CD40.

15 October 2026, Eur J Endocrinol.

On OnCo: CD40, PSIP1

Paper: A Meta-Analysis on Outcomes of Zanidatamab Plus Chemotherapy in Patients with Advanced HER2-positive Gastroesophageal Adenocarcinoma.

2026-10-15T00:00:00Z

Published in J Gastrointest Cancer on 15 October 2026; matched the OnCo record for Tislelizumab.

15 October 2026, J Gastrointest Cancer.

On OnCo: Tislelizumab, Zanidatamab

Paper: A Nanodelivery Platform Harnessing Synthetic Lethality and Efferocytosis Inhibition for Synergistically Enhanced Immunotherapy of Triple-Negative Breast Cancer.

2026-10-15T00:00:00Z

Published in Small on 15 October 2026; matched the OnCo record for PLK1.

15 October 2026, Small.

On OnCo: PLK1

Paper: A Pilot Study of Condensed Busulfan, Melphalan, and Fludarabine Myeloablative Conditioning in Ex Vivo CD34-Selected Allogeneic Hematopoietic Cell Transplantation.

2026-10-15T00:00:00Z

Published in Transplant Cell Ther on 15 October 2026; matched the OnCo record for Busulfan.

15 October 2026, Transplant Cell Ther.

On OnCo: Busulfan, Melphalan

Paper: A Remotely Delivered Exercise-Based Rehabilitation Program for Patients with Persistent Chemotherapy-Induced Peripheral Neuropathy (EX-CIPN): A Phase I Feasibility Trial.

2026-10-15T00:00:00Z

Published in Curr Oncol on 15 October 2026; found by the roadmap watch for EX-CIPN: virtual exercise-based rehabilitation for persistent chemotherapy nerve damage.

15 October 2026, Curr Oncol.

On OnCo: EX-CIPN: virtual exercise-based rehabilitation for persistent chemotherapy nerve damage, Recovery and rejuvenation roadmap: cure is not enough → survivorship gets a name → the cohorts that measured the cost → exercise proven as treatment → biological ageing measured and sold → repair, if anyone funds it

Paper: Apalutamide in prostate cancer: clinical evidence, disease modification hypothesis, and emerging treatment de‑intensification strategies.

2026-10-15T00:00:00Z

Published in Expert Rev Anticancer Ther on 15 October 2026; matched the OnCo record for Apalutamide.

15 October 2026, Expert Rev Anticancer Ther.

On OnCo: Apalutamide

Paper: Association of Life's Essential 8 With Clonal Hematopoiesis and Coronary Artery Disease.

2026-10-15T00:00:00Z

Published in JACC CardioOncol on 15 October 2026; matched the OnCo record for ASXL1.

15 October 2026, JACC CardioOncol.

On OnCo: ASXL1

Paper: Behind the Sella: A Rare Case of Pituicytoma Mimicking a Pituitary Adenoma.

2026-10-15T00:00:00Z

Published in Am J Case Rep on 15 October 2026; matched the OnCo record for Lactotroph pituitary neuroendocrine tumour.

15 October 2026, Am J Case Rep.

On OnCo: Lactotroph pituitary neuroendocrine tumour

Paper: Beyond Reirradiation: Third-Course Radiation Therapy in Recurrent Diffuse Intrinsic Pontine Glioma-Case Series and Literature Review.

2026-10-15T00:00:00Z

Published in J Pediatr Hematol Oncol on 15 October 2026; matched the OnCo record for Diffuse midline glioma, H3 K27-altered.

15 October 2026, J Pediatr Hematol Oncol.

On OnCo: Diffuse midline glioma, H3 K27-altered

Paper: Bispecific NK-Cell Engager Targeting TP53 Mutation Through Integration of a TCR-mimic Antibody.

2026-10-15T00:00:00Z

Published in MedComm (2020) on 15 October 2026; matched the OnCo record for NK cell engagers.

15 October 2026, MedComm (2020).

On OnCo: NK cell engagers

Paper: Brain-Specific Quantification of Somatostatin Receptor Expression: SUVmax and SUVRsss as Quantitative Correlates of the Krenning Score in Meningioma.

2026-10-15T00:00:00Z

Published in J Nucl Med on 15 October 2026; matched the OnCo record for Somatostatin analogues.

15 October 2026, J Nucl Med.

On OnCo: Somatostatin analogues, Peptide receptor radionuclide therapy

Paper: Calcified Pleural Dissemination and Malignant Pleural Effusion in Dedifferentiated Chondrosarcoma: A Case Report with an Institutional Review.

2026-10-15T00:00:00Z

Published in Intern Med on 15 October 2026; matched the OnCo record for Chondrosarcoma.

15 October 2026, Intern Med.

On OnCo: Chondrosarcoma

Paper: Can Simple MRI Characteristics Predict Molecular Subgroups in Paediatric Medulloblastoma?

2026-10-15T00:00:00Z

Published in J Med Imaging Radiat Oncol on 15 October 2026; matched the OnCo record for Group 3 and group 4 medulloblastoma.

15 October 2026, J Med Imaging Radiat Oncol.

On OnCo: Group 3 and group 4 medulloblastoma, SHH-activated medulloblastoma

Paper: CD70-Targeted PET/CT in a Patient with von Hippel-Lindau Syndrome and Clear Cell Renal Cell Carcinoma.

2026-10-15T00:00:00Z

Published in J Nucl Med on 15 October 2026; matched the OnCo record for CD70.

15 October 2026, J Nucl Med.

On OnCo: CD70

Paper: CDK4/6 inhibition radiosensitizes p16-negative squamous cell carcinomas of the aerodigestive tract via cell cycle arrest.

2026-10-15T00:00:00Z

Published in Int J Radiat Biol on 15 October 2026; matched the OnCo record for Abemaciclib.

15 October 2026, Int J Radiat Biol.

On OnCo: Abemaciclib

Paper: Cerebrospinal Fluid Tumor-Derived DNA Analysis Aids in the Diagnosis of Postpartum Diffuse Midline Glioma.

2026-10-15T00:00:00Z

Published in Oncologist on 15 October 2026; matched the OnCo record for Diffuse midline glioma, H3 K27-altered.

15 October 2026, Oncologist.

On OnCo: Diffuse midline glioma, H3 K27-altered, Dordaviprone, Histone H3.3

Paper: Clinical Characteristics of Intracranial Hemorrhage in Pediatric Acute Leukemia.

2026-10-15T00:00:00Z

Published in Pediatr Blood Cancer on 15 October 2026; matched the OnCo record for KMT2A (MLL) rearrangement.

15 October 2026, Pediatr Blood Cancer.

On OnCo: KMT2A (MLL) rearrangement

Paper: Clinical relevance of the newly reclassified HLA-C*04:09L low-expression allele in allogeneic hematopoietic cell transplantation: a case report.

2026-10-15T00:00:00Z

Published in Transpl Immunol on 15 October 2026; matched the OnCo record for HLA-C.

15 October 2026, Transpl Immunol.

On OnCo: HLA-C

Paper: Clinical translation of targeted alpha therapy: safety, dosimetry, radiation protection, and regulatory considerations.

2026-10-15T00:00:00Z

Published in Semin Nucl Med on 15 October 2026; matched the OnCo record for Targeted alpha therapy.

15 October 2026, Semin Nucl Med.

On OnCo: Targeted alpha therapy

Paper: Combination therapy for BCG-unresponsive non-muscle-invasive bladder cancer: biological rationale and ongoing clinical strategies.

2026-10-15T00:00:00Z

Published in Nat Rev Urol on 15 October 2026; matched the OnCo record for Nadofaragene firadenovec.

15 October 2026, Nat Rev Urol.

On OnCo: Nadofaragene firadenovec, Valrubicin

Paper: Correction: Transoral Robotic Surgery (TORS) versus radical radiotherapy following neoadjuvant therapy for oropharyngeal carcinoma: a multicenter, real-world efficacy and safety analysis.

2026-10-15T00:00:00Z

Published in J Robot Surg on 15 October 2026; matched the OnCo record for Transoral robotic surgery.

15 October 2026, J Robot Surg.

On OnCo: Transoral robotic surgery

Paper: Correspondence of Papillary Thyroid Cancer With Cutaneous Metastasis in Thyroidology.

2026-10-15T00:00:00Z

Published in World J Otorhinolaryngol Head Neck Surg on 15 October 2026; matched the OnCo record for PAX8.

15 October 2026, World J Otorhinolaryngol Head Neck Surg.

On OnCo: PAX8

Paper: Cost-effectiveness of amivantamab plus lazertinib and osimertinib plus chemotherapy versus osimertinib monotherapy for first-line EGFR-mutated advanced non-small cell lung cancer: an updated analysis.

2026-10-15T00:00:00Z

Published in Expert Rev Pharmacoecon Outcomes Res on 15 October 2026; matched the OnCo record for Amivantamab.

15 October 2026, Expert Rev Pharmacoecon Outcomes Res.

On OnCo: Amivantamab, Lazertinib

Paper: Cost-Effectiveness of Telisotuzumab Vedotin-tllv for Previously Treated High c-Met Protein-Overexpressing Nonsquamous Non-Small Cell Lung Cancer in the United States.

2026-10-15T00:00:00Z

Published in Value Health on 15 October 2026; matched the OnCo record for Telisotuzumab vedotin.

15 October 2026, Value Health.

On OnCo: Telisotuzumab vedotin

Paper: CRISPR-based interrogation of alternative lengthening of telomeres: mapping dependencies, stress-buffering pathways, and therapeutic vulnerabilities.

2026-10-15T00:00:00Z

Published in Cancer Lett on 15 October 2026; matched the OnCo record for FANCM.

15 October 2026, Cancer Lett.

On OnCo: FANCM

Paper: Cullin-5 RING E3 ligase limits CD8⁺ T-cell persistence and effector responses during chronic antigen stimulation.

2026-10-15T00:00:00Z

Published in Cancer Immunol Res on 15 October 2026; matched the OnCo record for CTAG1B.

15 October 2026, Cancer Immunol Res.

On OnCo: CTAG1B, Pevonedistat

Paper: Current management and emerging pharmacotherapeutic strategies in acute promyelocytic leukemia.

2026-10-15T00:00:00Z

Published in Expert Opin Pharmacother on 15 October 2026; matched the OnCo record for Arsenic trioxide.

15 October 2026, Expert Opin Pharmacother.

On OnCo: Arsenic trioxide, CD33, Gemtuzumab ozogamicin

Paper: CXM102 Regulates the Multiple Differentiation and Anti-Inflammation of Human Bone Marrow-Derived Leptin Receptor-Positive Stromal Cells In Vitro.

2026-10-15T00:00:00Z

Published in Stem Cells Dev on 15 October 2026; matched the OnCo record for LEPR.

15 October 2026, Stem Cells Dev.

On OnCo: LEPR

Paper: Cytopathology and Prognostic Accuracy of 15-GEP/PRAME: The Collaborative Ocular Oncology Group Study 2.

2026-10-15T00:00:00Z

Published in JAMA Ophthalmol on 15 October 2026; matched the OnCo record for PRAME.

15 October 2026, JAMA Ophthalmol.

On OnCo: PRAME, Uveal melanoma

Paper: Decoupling T cell cytotoxicity: a CCL21+ICAM1-based synthetic immune niche enhances tumor elimination by accelerating lytic hit delivery.

2026-10-15T00:00:00Z

Published on 15 October 2026 after first appearing as a preprint; matched CD8.

15 October 2026.

On OnCo: CD8

Paper: Diet quality and prognosis in patients with non-muscle invasive bladder cancer: the Be-Well Study.

2026-10-15T00:00:00Z

Published in Urology on 15 October 2026; matched the OnCo record for Mitomycin C.

15 October 2026, Urology.

On OnCo: Mitomycin C

Paper: Disruption of the CRL5 ubiquitin ligase complex enhances engineered T-cell persistence under chronic tumor antigen exposure.

2026-10-15T00:00:00Z

Published in Cancer Immunol Res on 15 October 2026; matched the OnCo record for Cytokines & engineered cytokines.

15 October 2026, Cancer Immunol Res.

On OnCo: Cytokines & engineered cytokines

Paper: Disseminated Mixed Lytic-Sclerotic Skeletal Metastases as Initial Presentation of Gallbladder Carcinoma: A Case Report.

2026-10-15T00:00:00Z

Published in Clin Case Rep on 15 October 2026; matched the OnCo record for Gallbladder cancer.

15 October 2026, Clin Case Rep.

On OnCo: Gallbladder cancer

Paper: Early Local Tumour Control and Feasibility of Intratumoral P-32 Microparticle Implantation in Patients with Locally Advanced Pancreatic Cancer: A Prospective Single-Center Observational Cohort Study.

2026-10-15T00:00:00Z

Published on 15 October 2026 after first appearing as a preprint; matched Nab-paclitaxel, SPECT & bone scan and Gemcitabine.

15 October 2026.

On OnCo: Nab-paclitaxel, SPECT & bone scan, Gemcitabine, Phosphorus-32, SPECT/CT

Paper: Efficacy of continuous ibrutinib monotherapy in patients with relapsed/refractory chronic lymphocytic leukemia with high-burden and low-burden TP53 mutations: Multicenter retrospective analysis of the Polish Adult Leukemia Group (PALG).

2026-10-15T00:00:00Z

Published in Adv Clin Exp Med on 15 October 2026; matched the OnCo record for Relapsed or refractory chronic lymphocytic leukaemia.

15 October 2026, Adv Clin Exp Med.

On OnCo: Relapsed or refractory chronic lymphocytic leukaemia

Paper: Emergence of inactivating NOTCH1 mutations in an IDH-mutant astrocytoma with clinical resistance to vorasidenib treatment.

2026-10-15T00:00:00Z

Published in Neuro Oncol on 15 October 2026; matched the OnCo record for Astrocytoma, IDH-mutant.

15 October 2026, Neuro Oncol.

On OnCo: Astrocytoma, IDH-mutant, Vorasidenib

Paper: Environmental chemical mixtures reprogram mammary epithelial development to epigenetic states associated with breast cancer.

2026-10-15T00:00:00Z

Published on 15 October 2026 after first appearing as a preprint; matched DNA methylation profiling.

15 October 2026.

On OnCo: DNA methylation profiling

Paper: EQUIPOISE: EQUivalence In Prostate cancer treatment: surgery Or radiotherapy? An Intention-to-treat Survival analysis from real-world Evidence.

2026-10-15T00:00:00Z

Published in World J Urol on 15 October 2026; matched the OnCo record for SCN9A.

15 October 2026, World J Urol.

On OnCo: SCN9A

Paper: Fanconi Anemia: Matrix Remodeling and Oral Carcinogenesis.

2026-10-15T00:00:00Z

Published in J Dent Res on 15 October 2026; matched the OnCo record for FANCA.

15 October 2026, J Dent Res.

On OnCo: FANCA

Paper: Flow MRD pre-blinatumomab consolidation, despite subsequent clearance, is associated with inferior survival in Ph+ B-ALL.

2026-10-15T00:00:00Z

Published in Blood Adv on 15 October 2026; matched the OnCo record for Blinatumomab.

15 October 2026, Blood Adv.

On OnCo: Blinatumomab, IKZF1

Paper: FOXC2 regulates macrophage polarization and osteosarcoma progression via the CXCL12/CXCR4 signaling axis.

2026-10-15T00:00:00Z

Published in J Pathol on 15 October 2026; matched the OnCo record for FOXC2.

15 October 2026, J Pathol.

On OnCo: FOXC2

Paper: Genomic characterization of advanced and recurrent endometrial carcinoma: KRAS and TP53 co-mutation as a biomarker for adverse prognosis and therapeutic failure.

2026-10-15T00:00:00Z

Published in Gynecol Oncol on 15 October 2026; matched the OnCo record for Advanced or recurrent endometrial cancer.

15 October 2026, Gynecol Oncol.

On OnCo: Advanced or recurrent endometrial cancer

Paper: Hematopoietic cell transplantation using treosulfan-based conditioning for IL-10 receptor deficiency.

2026-10-15T00:00:00Z

Published in J Hum Immun on 15 October 2026; matched the OnCo record for Interleukin-10.

15 October 2026, J Hum Immun.

On OnCo: Interleukin-10, Treosulfan

Paper: Hidden in Plain Sight: Gastric Adenocarcinoma in Endoscopically Normal Mucosa in a CDH1 Mutation Carrier.

2026-10-15T00:00:00Z

Published in ACG Case Rep J on 15 October 2026; matched the OnCo record for CDH1.

15 October 2026, ACG Case Rep J.

On OnCo: CDH1

Paper: Histone H3K27 methylation states are sequentially catalyzed in cycling cells.

2026-10-15T00:00:00Z

Published on 15 October 2026 after first appearing as a preprint; matched EZH2 and H3C14.

15 October 2026.

On OnCo: EZH2, H3C14

Paper: Histopathological and immunohistochemical analyses do not indicate timing of prophylactic hysterectomy: a retrospective analysis of endometrial biopsies in Lynch syndrome carriers.

2026-10-15T00:00:00Z

Published in Fam Cancer on 15 October 2026; matched the OnCo record for ARID1A.

15 October 2026, Fam Cancer.

On OnCo: ARID1A

Paper: HLA profiles and susceptibility to Alveolar echinococcosis: evidence from a large cohort with population and household controls.

2026-10-15T00:00:00Z

Published in Emerg Microbes Infect on 15 October 2026; matched the OnCo record for HLA-A.

15 October 2026, Emerg Microbes Infect.

On OnCo: HLA-A

Paper: Hyperinflammatory differentiation syndrome with hemophagocytic lymphohistiocytosis-like features following menin inhibition in acute myeloid leukemia.

2026-10-15T00:00:00Z

Published in Haematologica on 15 October 2026; matched the OnCo record for Menin.

15 October 2026, Haematologica.

On OnCo: Menin

Paper: Identifying facilitators of and barriers to digital health literacy in pediatric rheumatic disease: A scoping review.

2026-10-15T00:00:00Z

Published in PLOS Digit Health on 15 October 2026; matched the OnCo record for High-grade B-cell lymphoma with MYC and BCL2 rearrangements.

15 October 2026, PLOS Digit Health.

On OnCo: High-grade B-cell lymphoma with MYC and BCL2 rearrangements

Paper: Immunohistochemical Analysis of INSM1, MCPyV, and PHOX2B Expression in Merkel Cell Carcinoma.

2026-10-15T00:00:00Z

Published in Am J Dermatopathol on 15 October 2026; matched the OnCo record for PHOX2B.

15 October 2026, Am J Dermatopathol.

On OnCo: PHOX2B

Paper: Impact of adjuvant treatment on survival in surgically staged 2009 FIGO stage I uterine serous carcinoma.

2026-10-15T00:00:00Z

Published in Gynecol Oncol on 15 October 2026; matched the OnCo record for p53-abnormal endometrial cancer, including uterine serous carcinoma.

15 October 2026, Gynecol Oncol.

On OnCo: p53-abnormal endometrial cancer, including uterine serous carcinoma

Paper: Impact of comedication on survival and toxicity in patients treated with systemic therapy for unresectable hepatocellular carcinoma.

2026-10-15T00:00:00Z

Published in J Oncol Pharm Pract on 15 October 2026; matched the OnCo record for Tremelimumab.

15 October 2026, J Oncol Pharm Pract.

On OnCo: Tremelimumab

Paper: Infectious, Environmental, and Chronic Disease Burden among 1,844 Newly Arrived Humanitarian Migrants in Oklahoma, 2019-2025.

2026-10-15T00:00:00Z

Published in Am J Trop Med Hyg on 15 October 2026; matched the OnCo record for Ivermectin.

15 October 2026, Am J Trop Med Hyg.

On OnCo: Ivermectin

Paper: Integrated identification of CYP1A1 and CYP1B1 as potential drivers of smoking-related lung carcinogenesis.

2026-10-15T00:00:00Z

Published in 3 Biotech on 15 October 2026; matched the OnCo record for CYP1B1.

15 October 2026, 3 Biotech.

On OnCo: CYP1B1, HLA-DR, HLA-DRA

Paper: Integrated models of palliative medicine and pain management for the treatment of cancer-related pain: a review.

2026-10-15T00:00:00Z

Published in Curr Opin Support Palliat Care on 15 October 2026; matched the OnCo record for Cancer pain management.

15 October 2026, Curr Opin Support Palliat Care.

On OnCo: Cancer pain management

Paper: Investigating potential prognostic genes and candidate therapeutic targets for acute myeloid leukemia in food-medicine homologous plants via integrated network pharmacology and transcriptomics.

2026-10-15T00:00:00Z

Published in Naunyn Schmiedebergs Arch Pharmacol on 15 October 2026; matched the OnCo record for ITGB3.

15 October 2026, Naunyn Schmiedebergs Arch Pharmacol.

On OnCo: ITGB3, MYB, MYBL1

Paper: Loncastuximab and Rituximab in Elderly Unfit/Frail Patients With Previously Untreated Diffuse Large B-Cell Lymphoma.

2026-10-15T00:00:00Z

Published in Blood Adv on 15 October 2026; matched the OnCo record for Loncastuximab tesirine.

15 October 2026, Blood Adv.

On OnCo: Loncastuximab tesirine

Paper: Long-lasting Inhibition of L-type Amino Acid Transporter 1 by Nanvuranlat is Associated with Prolonged Cellular Retention Counteracted by Cancer-type OATP1B3 in Cholangiocarcinoma Cells.

2026-10-15T00:00:00Z

Published in Pharm Res on 15 October 2026; matched the OnCo record for NVL.

15 October 2026, Pharm Res.

On OnCo: NVL

Paper: Lung cancer incidence, metastatic disease and mortality in people accessing mental health services: Opportunities for screening.

2026-10-15T00:00:00Z

Published in Aust N Z J Psychiatry on 15 October 2026; matched the OnCo record for NHS Targeted Lung Health Check.

15 October 2026, Aust N Z J Psychiatry.

On OnCo: NHS Targeted Lung Health Check

Paper: Lymphangiogenesis driven by VEGF-C reshapes tumor immune landscape and enables tumor eradication by viral immunotherapy in mouse melanoma models.

2026-10-15T00:00:00Z

Published in Cell Rep on 15 October 2026; matched the OnCo record for VEGFC.

15 October 2026, Cell Rep.

On OnCo: VEGFC

Paper: MACC1 in colorectal cancer: a claim-level evidence audit from metastasis driver to proposed microenvironmental regulator.

2026-10-15T00:00:00Z

Published in Clin Transl Oncol on 15 October 2026; matched the OnCo record for MACC1.

15 October 2026, Clin Transl Oncol.

On OnCo: MACC1

Paper: Machine Learning Models Combining [68Ga]Ga-PSMA-11 PET Radiomics and Clinical Features to Predict Overall Survival for Metastatic Castration-resistant Prostate Cancer Treated with [177Lu]Lu-PSMA Radioligand Therapy.

2026-10-15T00:00:00Z

Published in Eur Urol Oncol on 15 October 2026; matched the OnCo record for Gallium-68 gozetotide.

15 October 2026, Eur Urol Oncol.

On OnCo: Gallium-68 gozetotide, Lutetium-177 radioligand therapy

Paper: Mechanical ventilation before and during veno-venous extracorporeal membrane oxygenation.

2026-10-15T00:00:00Z

Published in Expert Rev Med Devices on 15 October 2026; matched the OnCo record for Visual inspection with acetic acid (VIA) for cervical screening.

15 October 2026, Expert Rev Med Devices.

On OnCo: Visual inspection with acetic acid (VIA) for cervical screening

Paper: Mechanistic insights and therapeutic implications of mitoxyperilysis: a spatially gated mitochondria-dependent lytic cell death.

2026-10-15T00:00:00Z

Published in Apoptosis on 15 October 2026; matched the OnCo record for RICTOR.

15 October 2026, Apoptosis.

On OnCo: RICTOR

Paper: Moderate-risk variants in hereditary breast and ovarian cancer: seven-year experience from a specialized center.

2026-10-15T00:00:00Z

Published in Fam Cancer on 15 October 2026; matched the OnCo record for BARD1.

15 October 2026, Fam Cancer.

On OnCo: BARD1, CHEK2, RAD51C, RAD51D

Paper: Molecular Mechanisms and Therapeutic Advances in KRAS G12C-Mutant Non-Small Cell Lung Cancer: Toward Mechanism-Guided Longitudinal Management.

2026-10-15T00:00:00Z

Published in Cancer Innov on 15 October 2026; matched the OnCo record for Adagrasib.

15 October 2026, Cancer Innov.

On OnCo: Adagrasib, KRAS G12C-mutant non-small-cell lung cancer, Sotorasib, STK11

Paper: Multidisciplinary Management of a Giant Ovarian Sertoli-Leydig Cell Tumor Presenting With Isosexual Precocious Puberty: A Pediatric Case Report.

2026-10-15T00:00:00Z

Published in Clin Case Rep on 15 October 2026; matched the OnCo record for Leydig cell tumour of the testis.

15 October 2026, Clin Case Rep.

On OnCo: Leydig cell tumour of the testis

Paper: Multimodal assessment of exceptional responders refines subtyping-directed precision treatment in HR+/HER2- breast cancer.

2026-10-15T00:00:00Z

Published in J Clin Invest on 15 October 2026; matched the OnCo record for Rivoceranib.

15 October 2026, J Clin Invest.

On OnCo: Rivoceranib

Paper: Multimodal based Brain Tumor Classification using Clustered Federated Learning in Edge based IoT Network.

2026-10-15T00:00:00Z

Published in Int J Neurosci on 15 October 2026; matched the OnCo record for TPR.

15 October 2026, Int J Neurosci.

On OnCo: TPR

Paper: NeoBridge: Biophysics-informed neoantigen prioritization and clonal architecture profiling in pancreatic cancer.

2026-10-15T00:00:00Z

Published in Cell Genom on 15 October 2026; matched the OnCo record for Personalised neoantigen (mRNA) vaccines.

15 October 2026, Cell Genom.

On OnCo: Personalised neoantigen (mRNA) vaccines

Paper: New Horizons in Pharmacotherapy for Cushing's Disease and Acromegaly.

2026-10-15T00:00:00Z

Published in Endocr Relat Cancer on 15 October 2026; matched the OnCo record for Somatostatin analogues.

15 October 2026, Endocr Relat Cancer.

On OnCo: Somatostatin analogues, Pegvisomant, Somatotroph pituitary neuroendocrine tumour

Paper: Nine Years of Vemurafenib Therapy in BRAF V600E-Positive Multisystem Langerhans Cell Histiocytosis with Asymptomatic Neurodegenerative Changes.

2026-10-15T00:00:00Z

Published in Indian J Pediatr on 15 October 2026; matched the OnCo record for Langerhans cell histiocytosis.

15 October 2026, Indian J Pediatr.

On OnCo: Langerhans cell histiocytosis, Multisystem Langerhans cell histiocytosis

Paper: Novel antibody-based regimens for large B-cell lymphoma: latest updates from the 2026 ASCO Annual Meeting.

2026-10-15T00:00:00Z

Published in J Hematol Oncol on 15 October 2026; matched the OnCo record for CD79b.

15 October 2026, J Hematol Oncol.

On OnCo: CD79b, Epcoritamab, Mosunetuzumab, Polatuzumab vedotin, Tafasitamab

Paper: OAS-nano: the Observed VHH Space Database.

2026-10-15T00:00:00Z

Published in Nucleic Acids Res on 15 October 2026; matched the OnCo record for CTAG2.

15 October 2026, Nucleic Acids Res.

On OnCo: CTAG2

Paper: Oral azacitidine as time-limited, PCR-dependent maintenance in acute myeloid leukemia with inv(16): two case reports.

2026-10-15T00:00:00Z

Published in Leuk Lymphoma on 15 October 2026; matched the OnCo record for CBFB.

15 October 2026, Leuk Lymphoma.

On OnCo: CBFB, MYH11

Paper: Overcoming the nuclear barrier in nonviral gene therapy: mechanisms, carrier design, and translational perspectives on NLS peptide and DNA targeting sequence strategies.

2026-10-15T00:00:00Z

Published in Drug Deliv on 15 October 2026; matched the OnCo record for Nogapendekin alfa inbakicept.

15 October 2026, Drug Deliv.

On OnCo: Nogapendekin alfa inbakicept

Paper: Pharmacological inhibition of MCL-1 disrupts mitochondrial cristae and depletes the human neural progenitor cell pool.

2026-10-15T00:00:00Z

Published in J Cell Sci on 15 October 2026; matched the OnCo record for MED12.

15 October 2026, J Cell Sci.

On OnCo: MED12

Paper: Pharmacophore modelling-based screening of natural allosteric EGFR inhibitors using molecular docking, DFT, and molecular dynamics simulations.

2026-10-15T00:00:00Z

Published in J Mol Graph Model on 15 October 2026; matched the OnCo record for Cetuximab.

15 October 2026, J Mol Graph Model.

On OnCo: Cetuximab

Paper: Plant DICER-LIKE, dual measurement RNA rulers.

2026-10-15T00:00:00Z

Published in Curr Opin Plant Biol on 15 October 2026; matched the OnCo record for DICER1.

15 October 2026, Curr Opin Plant Biol.

On OnCo: DICER1

Paper: Post-Transplant Lymphoproliferative Disorder After Successful Treatment of Graft-Versus Host Disease Following Liver Transplantation.

2026-10-15T00:00:00Z

Published in Transplant Proc on 15 October 2026; matched the OnCo record for Post-transplant lymphoproliferative disorder.

15 October 2026, Transplant Proc.

On OnCo: Post-transplant lymphoproliferative disorder

Paper: Precision Medicine in Sickle Cell Disease: From Molecular Pathways to Curative Strategies.

2026-10-15T00:00:00Z

Published in Hemoglobin on 15 October 2026; matched the OnCo record for BCL11A.

15 October 2026, Hemoglobin.

On OnCo: BCL11A, MYB, MYBL1

Paper: Preclinical efficacy of a systemically-administered, second-generation STING agonist that promotes anti-tumour immunity in combination with radiotherapy.

2026-10-15T00:00:00Z

Published on 15 October 2026 after first appearing as a preprint; matched Immune checkpoint inhibitors, STING & innate immune agonists and PD-1.

15 October 2026.

On OnCo: Immune checkpoint inhibitors, STING & innate immune agonists, PD-1, PD-L1, CTLA-4, CD8

Paper: Prediction of immunotherapy response using live tumor fragments from routine clinical biopsies.

2026-10-15T00:00:00Z

Published in Cell Rep Med on 15 October 2026; matched the OnCo record for Companion diagnostics.

15 October 2026, Cell Rep Med.

On OnCo: Companion diagnostics, Immune checkpoint inhibitors

Paper: Prefoldin Subunit 2 Promotes Migration of Hepatocellular Carcinoma Cells and Is Associated with Poor Prognosis.

2026-10-15T00:00:00Z

Published in Ann Surg Oncol on 15 October 2026; matched the OnCo record for HLF.

15 October 2026, Ann Surg Oncol.

On OnCo: HLF, RAC1

Paper: Primary Pure Yolk Sac Tumor of the Urinary Bladder: A Case Report.

2026-10-15T00:00:00Z

Published in IJU Case Rep on 15 October 2026; matched the OnCo record for Etoposide.

15 October 2026, IJU Case Rep.

On OnCo: Etoposide, Glypican-3, SALL4, Yolk sac tumour of the testis, postpubertal type

Paper: Prognosis and treatment-related toxicities in Down syndrome acute lymphoblastic leukemia in JCCG ALL-B12.

2026-10-15T00:00:00Z

Published in Blood Adv on 15 October 2026; matched the OnCo record for CRLF2.

15 October 2026, Blood Adv.

On OnCo: CRLF2

Paper: PTEN-loss confers dependence on the guanylate synthesis enzyme IMPDH in T-cell acute lymphoblastic leukemia.

2026-10-15T00:00:00Z

Published on 15 October 2026 after first appearing as a preprint; matched AKT and PTEN.

15 October 2026.

On OnCo: AKT, PTEN

Paper: Putrescine alters the composition of interstitial dendritic cell subsets by suppressing Cybb-dependent oxidative phosphorylation.

2026-10-15T00:00:00Z

Published in Immunobiology on 15 October 2026; matched the OnCo record for POLD1.

15 October 2026, Immunobiology.

On OnCo: POLD1

Paper: Real-world comparison of sonidegib and vismodegib in advanced basal cell carcinoma.

2026-10-15T00:00:00Z

Published in J Eur Acad Dermatol Venereol on 15 October 2026; matched the OnCo record for Locally advanced and metastatic basal cell carcinoma.

15 October 2026, J Eur Acad Dermatol Venereol.

On OnCo: Locally advanced and metastatic basal cell carcinoma, Sonidegib, Vismodegib

Paper: Real-World Treatment Patterns, Burden of Illness, and Survival of Autologous Stem Cell Transplant-Ineligible Patients With Mantle Cell Lymphoma in Ontario, Canada.

2026-10-15T00:00:00Z

Published in EJHaem on 15 October 2026; matched the OnCo record for Autologous stem cell transplant.

15 October 2026, EJHaem.

On OnCo: Autologous stem cell transplant, Bendamustine

Paper: Real-World Use of Dinutuximab Beta for High-Risk Neuroblastoma in Clinical Settings in France: The QUATUOR Study.

2026-10-15T00:00:00Z

Published in J Pediatr Hematol Oncol on 15 October 2026; matched the OnCo record for Dinutuximab (ch14.18) / dinutuximab beta.

15 October 2026, J Pediatr Hematol Oncol.

On OnCo: Dinutuximab (ch14.18) / dinutuximab beta

Paper: Reduced-dose pegylated asparaginase reliably achieves therapeutic levels in adult patients with acute lymphoblastic leukaemia and lymphoblastic lymphoma.

2026-10-15T00:00:00Z

Published in Br J Haematol on 15 October 2026; matched the OnCo record for Acute lymphoblastic leukaemia.

15 October 2026, Br J Haematol.

On OnCo: Acute lymphoblastic leukaemia, Asparaginase

Paper: Response to Venetoclax and Azacitidine in Induction-Refractory Adult Acute Myeloid Leukemia with UBTF Tandem Duplication and Associated Aberrant Splicing: A Case Report.

2026-10-15T00:00:00Z

Published in Intern Med on 15 October 2026; matched the OnCo record for UBTF.

15 October 2026, Intern Med.

On OnCo: UBTF

Approval: FDA approves belzutifan in combination with lenvatinib for advanced renal cell carcinoma with a clear cell component

2026-09-24T00:00:00Z

On September 24, 2026, the Food and Drug Administration approved belzutifan (Welireg, Merck & Co., Inc.) in combination with lenvatinib (Lenvima, Eisai Inc.) for adults with advanced renal cell carcinoma with a clear cell component (ccRCC) following a programmed death receptor-1 (PD-1) or programmed death-ligand 1 (PD-L1) inhibitor.

24 September 2026, FDA.

On OnCo: Lenvatinib, Belzutifan, Renal cell carcinoma, Clear cell renal cell carcinoma, Spinal cord tumours, Pancreatic neuroendocrine tumours, Hereditary pheochromocytoma and paraganglioma, Hepatocellular carcinoma, Advanced hepatocellular carcinoma, Intermediate hepatocellular carcinoma, Thyroid cancer

Approval: FDA approves lirafugratinib for previously treated, unresectable, locally advanced or metastatic cholangiocarcinoma

2026-09-23T00:00:00Z

On September 23, 2026, the Food and Drug Administration approved lirafugratinib (Lyrfigtu, Elevar Therapeutics, Inc.), a kinase inhibitor, for the treatment of adults with previously treated unresectable, locally advanced or metastatic cholangiocarcinoma harboring a fibroblast growth factor receptor 2 (FGFR2) gene fusion or other rearrangement.

23 September 2026, FDA.

On OnCo: Lirafugratinib, Biliary tract cancer, FGFR2

Approval: FDA approves imlunestrant in combination with abemaciclib for ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer

2026-09-18T00:00:00Z

On September 18, 2026, the Food and Drug Administration approved imlunestrant (Inluriyo) in combination with abemaciclib (Verzenio), for adults with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative, estrogen receptor 1 (ESR1)-mutated advanced or metastatic breast cancer, as detected by an FDA-authorized test, with disease progression following at least one line of endocrine therapy.

18 September 2026, FDA.

On OnCo: Imlunestrant, Abemaciclib, HR-positive / HER2-negative breast cancer, Breast cancer, High-risk early HR-positive breast cancer, HR-positive metastatic breast cancer after CDK4/6 inhibitors, CDK4/6, Estrogen receptor

Approval: FDA grants accelerated approval to sevabertinib for locally advanced or metastatic non-squamous non-small cell lung cancer

2026-09-09T00:00:00Z

On September 9, 2026, the Food and Drug Administration granted accelerated approval to sevabertinib (Hyrnuo, Bayer Healthcare Pharmaceuticals Inc.), a kinase inhibitor, for adult patients with locally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC) whose tumors have HER2 (ERBB2) tyrosine kinase domain (TKD) activating mutations, as detected by an FDA-authorized test.

9 September 2026, FDA.

On OnCo: Sevabertinib, Lung cancer, Squamous cell carcinoma of the lung, Non-small-cell lung cancer, HER2-mutant non-small-cell lung cancer, HER2

Approval: Accelerated approval: Camizestrant (US)

2026-09-04T00:00:00Z

Accelerated approval (Etcamah) The confirmatory requirement was still open 0.0 years later, when the FDA's table was read.

4 September 2026, FDA.

On OnCo: Camizestrant, HR-positive / HER2-negative breast cancer, HR-positive metastatic breast cancer after CDK4/6 inhibitors, Estrogen receptor

Approval: FDA grants accelerated approval to camizestrant with a CDK4/6 inhibitor for ESR1-Mutated HR-positive, HER2-negative locally advanced or metastatic breast cancer

2026-09-04T00:00:00Z

On September 4, 2026, the Food and Drug Administration granted accelerated approval to camizestrant (Etcamah, AstraZeneca), an estrogen receptor antagonist, in combination with a CDK4/6 inhibitor (abemaciclib, palbociclib, or ribociclib) for adults with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer upon detection of estrogen receptor-1 (ESR1) mutation during aromatase inhibitor and CDK4/6 inhibitor therapy, based on an FDA-authorized test.

4 September 2026, FDA.

On OnCo: Camizestrant, Palbociclib, Abemaciclib, Ribociclib, Breast cancer, HR-positive / HER2-negative breast cancer

Withdrawal: Withdrawal: Adagrasib (US)

2026-09-01T00:00:00Z

Withdrawn: the indication came off the label 2.3 years after its accelerated approval.

1 September 2026, FDA.

On OnCo: Adagrasib, Non-small-cell lung cancer, Colorectal cancer, Pancreatic ductal adenocarcinoma, KRAS G12C-mutant colorectal cancer, KRAS G12C-mutant non-small-cell lung cancer

Approval: Approval: Daraxonrasib (US)

2026-08-26T00:00:00Z

NDA 220910 approved as Rasonque: adults with metastatic pancreatic adenocarcinoma who have received at least one prior systemic therapy or who are not candidates for multiagent systemic therapy.

26 August 2026, FDA.

On OnCo: Daraxonrasib, Pancreatic ductal adenocarcinoma, Metastatic pancreatic ductal adenocarcinoma, KRAS G12C-mutant pancreatic ductal adenocarcinoma, Non-small-cell lung cancer, Colorectal cancer

Approval: FDA approves daraxonrasib for metastatic pancreatic adenocarcinoma

2026-08-26T00:00:00Z

On August 26, 2026, the Food and Drug Administration approved daraxonrasib (RASONQUE, Revolution Medicines, Inc.), an inhibitor of the RAS GTPase family, for adults with metastatic pancreatic adenocarcinoma who have received at least one prior systemic therapy or who are not candidates for multiagent systemic therapy.

26 August 2026, FDA.

On OnCo: Daraxonrasib, Pancreatic ductal adenocarcinoma, Adenocarcinoma of the urethra, Adenocarcinoma of the lung

Withdrawal: Withdrawal: Tazemetostat (US)

2026-06-22T00:00:00Z

Withdrawn: the indication came off the label 6.4 years after its accelerated approval.

22 June 2026, FDA.

On OnCo: Tazemetostat, Follicular lymphoma, Sarcomas, EZH2

Withdrawal: Withdrawal: Tazemetostat (US)

2026-06-22T00:00:00Z

Withdrawn: the indication came off the label 6.0 years after its accelerated approval.

22 June 2026, FDA.

On OnCo: Tazemetostat, Follicular lymphoma, Sarcomas, EZH2

Withdrawal: Withdrawal: Selinexor (US)

2026-04-30T00:00:00Z

Withdrawn: the indication came off the label 5.9 years after its accelerated approval.

30 April 2026, FDA.

On OnCo: Selinexor, Endometrial cancer, Multiple myeloma, Diffuse large B-cell lymphoma, Relapsed or refractory multiple myeloma, TP53

Withdrawal: Withdrawal: Zelenectide pevedotin (US)

2026-03-01T00:00:00Z

Programme deprioritised after regulatory feedback on Duravelo-2 design.

March 2026, FDA.

On OnCo: Zelenectide pevedotin, Bladder & urothelial cancer, Nectin-4

Result: A Study of Lazertinib With Subcutaneous Amivantamab Compared With Intravenous Amivantamab in Participants With Epidermal Growth Factor Receptor: Phase 3 result

2026-01-01T00:00:00Z

For All Regions Other Than the European Union (EU) and Others Accepting Cycle 2 Day 1: Observed Serum Concentration (Ctrough) of Amivantamab at Steady State: Arm A: Lazertinib With Amivantamab SC-CF 206 micrograms per milliliters (mcg/ml) versus Arm B: Lazertinib With Amivantamab Intravenous (IV) Infusion 144 micrograms per milliliters (mcg/ml).

2026, ClinicalTrials.gov.

On OnCo: A Study of Lazertinib With Subcutaneous Amivantamab Compared With Intravenous Amivantamab in Participants With Epidermal Growth Factor Receptor, Lazertinib, Non-small-cell lung cancer, EGFR-mutated non-small-cell lung cancer

Result: A Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for the Treatment of Participants With Deleterious Germline or Somatic Homologous Recombination Repair: Phase 3 result

2026-01-01T00:00:00Z

Breast Cancer Gene (BRCA) Subgroup: Radiographic Progression-free Survival (rPFS) Assessed by Investigator: BRCA Subgroup: Placebo With Abiraterone Acetate Plus Prednisone 25.99 months, hazard ratio 0.515.

2026, ClinicalTrials.gov.

On OnCo: A Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for the Treatment of Participants With Deleterious Germline or Somatic Homologous Recombination Repair, Abiraterone acetate, Niraparib, Prednisone, Prostate cancer, Metastatic hormone-sensitive prostate cancer

Result: A Study of Nofazinlimab (CS1003) in Subjects With Advanced Hepatocellular Carcinoma: Phase 3 result

2026-01-01T00:00:00Z

Overall Survival (OS): Nofazinlimab + Lenvatinib 21.6 months versus Placebo + Lenvatinib 18.5 months.

2026, ClinicalTrials.gov.

On OnCo: A Study of Nofazinlimab (CS1003) in Subjects With Advanced Hepatocellular Carcinoma, Lenvatinib, Hepatocellular carcinoma, Advanced hepatocellular carcinoma

Result: A Study of Osimertinib With or Without Chemotherapy Versus Chemotherapy Alone as Neoadjuvant Therapy for Patients With EGFRm Positive Resectable Non-S: Phase 3 result

2026-01-01T00:00:00Z

Major Pathological Response (MPR) - IASLC Method: Osimertinib + Chemo 25.6 % versus Osimertinib 24.8 % versus Placebo + Chemo 1.7 %.

2026, ClinicalTrials.gov.

On OnCo: A Study of Osimertinib With or Without Chemotherapy Versus Chemotherapy Alone as Neoadjuvant Therapy for Patients With EGFRm Positive Resectable Non-S, Osimertinib, Cisplatin, Carboplatin, Pemetrexed, Non-small-cell lung cancer

Result: A Study of Subcutaneous Nivolumab + Relatlimab Fixed-dose Combination (FDC) in Previously Untreated Metastatic or Unresectable Melanoma: Phase 3 result

2026-01-01T00:00:00Z

Adjusted Time-Averaged Nivolumab Serum Concentration Over the First 28 Days (Cavgd28-Nivo) on Natural Logarithmic Scale: Nivo + Rela FDC SC 4.141 ug/ml versus Nivo + Rela FDC IV 3.901 ug/ml.

2026, ClinicalTrials.gov.

On OnCo: A Study of Subcutaneous Nivolumab + Relatlimab Fixed-dose Combination (FDC) in Previously Untreated Metastatic or Unresectable Melanoma, Nivolumab, Relatlimab + nivolumab, Melanoma, Advanced melanoma

Result: A Study of Subcutaneous Nivolumab Versus Intravenous Nivolumab in Participants With Previously Treated Clear Cell Renal Cell Carcinoma That is Advance: Phase 3 result

2026-01-01T00:00:00Z

Adjusted Geometric Mean Serum Concentration of Nivolumab Over 28 Days (Cavgd28) on Original Scale: Nivolumab SC 77.373 μg/ml versus Nivolumab IV 36.875 μg/ml versus Nivo SC Process C 75.504 μg/ml versus Nivo SC Process D 75.596 μg/ml.

2026, ClinicalTrials.gov.

On OnCo: A Study of Subcutaneous Nivolumab Versus Intravenous Nivolumab in Participants With Previously Treated Clear Cell Renal Cell Carcinoma That is Advance, Nivolumab, Renal cell carcinoma, Clear cell renal cell carcinoma

Result: A Study to Evaluate Chemotherapy Plus Osimertinib Against Chemotherapy Plus Placebo in Patients With Non-small Cell Lung Cancer: Phase 3 result

2026-01-01T00:00:00Z

Progression Free Survival (PFS): Treatment Arm A: Osimertinib (AZD9291), Pemetrexed, Cisplatin or Carboplatin 8.4 months versus Treatment Arm B: Placebo for Osimertinib (AZD9291), Pemetrexed, Cisplatin or Carboplatin 4.4 months, hazard ratio 0.43.

2026, ClinicalTrials.gov.

On OnCo: A Study to Evaluate Chemotherapy Plus Osimertinib Against Chemotherapy Plus Placebo in Patients With Non-small Cell Lung Cancer, Osimertinib, Non-small-cell lung cancer

Result: A Study to Investigate Tolerability and Efficacy of Asciminib: Phase 3 result

2026-01-01T00:00:00Z

Time to Discontinuation of Study Treatment Due to Adverse Event (TTDAE) (From Interim Analysis): Asciminib 16 participants versus Nilotinib 34 participants, hazard ratio 0.45.

2026, ClinicalTrials.gov.

On OnCo: A Study to Investigate Tolerability and Efficacy of Asciminib, Asciminib, Nilotinib, Chronic myeloid leukaemia, Chronic myeloid leukaemia, chronic phase

Result: ALTAIR: Phase 3 result

2026-01-01T00:00:00Z

Median disease-free survival 9.30 against 5.55 months (hazard ratio 0.79, p=0.107): primary endpoint not met.

2026, DOI.

On OnCo: ALTAIR, Trifluridine/tipiracil, Signatera, Colorectal cancer

Result: An Efficacy and Safety Study of Luspatercept (ACE-536) Versus Placebo in Subjects With Myeloproliferative Neoplasm-Associated Myelofibrosis on Concomi: Phase 3 result

2026-01-01T00:00:00Z

Red Blood Cell-transfusion Independence (RBC-TI) ≥ 12 Weeks (RBC-TI 12): Treatment 23.08 % versus Control 13.33 %.

2026, ClinicalTrials.gov.

On OnCo: An Efficacy and Safety Study of Luspatercept (ACE-536) Versus Placebo in Subjects With Myeloproliferative Neoplasm-Associated Myelofibrosis on Concomi, Luspatercept, Myeloproliferative neoplasms, Primary myelofibrosis

Result: BL-B01D1-307: Phase 3 result

2026-01-01T00:00:00Z

PFS and OS significantly improved at interim analysis (numbers presented ASCO 2026).

2026, onclive.com.

On OnCo: BL-B01D1-307, Izalontamab brengitecan, Triple-negative breast cancer

Result: Capivasertib+Paclitaxel as First Line Treatment for Patients With Locally Advanced or Metastatic TNBC: Phase 3 result

2026-01-01T00:00:00Z

Overall survival 17.7 vs 18.0 months (HR 0.92, p 0.32) overall and 20.4 vs 20.4 months (HR 1.05) in PIK3CA/AKT1/PTEN-altered tumours; PFS 5.6 vs 5.1 months (HR 0.72).

2026, DOI.

On OnCo: Capivasertib+Paclitaxel as First Line Treatment for Patients With Locally Advanced or Metastatic TNBC, Capivasertib, Paclitaxel / nab-paclitaxel, Triple-negative breast cancer, Metastatic triple-negative breast cancer

Result: CLARITY-Gastric 01: Phase 3 result

2026-01-01T00:00:00Z

Co-primary endpoints including OS met (July 2026); numbers pending.

2026, cancernetwork.com.

On OnCo: CLARITY-Gastric 01, Sonesitatug vedotin, Ramucirumab, Gastric & gastro-oesophageal junction cancer, Claudin 18.2

Result: DeLLphi-305: Phase 3 result

2026-01-01T00:00:00Z

Met the primary overall survival endpoint at the pre-specified interim analysis (Amgen, 8 September 2026); progression-free survival and response rate also improved; figures not yet disclosed.

2026, amgen.com.

On OnCo: DeLLphi-305, Tarlatamab, Durvalumab, Small-cell lung cancer, Extensive-stage small-cell lung cancer, DLL3

Result: DREAM3R: Phase 3 result

2026-01-01T00:00:00Z

Stopped early; primary endpoint not met.

2026, ClinicalTrials.gov.

On OnCo: DREAM3R, Durvalumab, Pemetrexed, Mesothelioma

Withdrawal: EU withdrawal: Duvelisib

2026-01-01T00:00:00Z

Marketing authorisation withdrawn in the European Union in 2026: Authorised May 2021; marketing authorisation withdrawn at Secura Bio's request 16 Feb 2026 (commercial reasons).

2026, European Commission (EMA opinion).

On OnCo: Duvelisib, Chronic lymphocytic leukaemia, Peripheral T-cell lymphomas, PIK3CA / PI3K-alpha

Withdrawal: EU withdrawal: Cinacalcet

2025-01-01T00:00:00Z

Marketing authorisation withdrawn in the European Union in 2025: Mimpara: authorised 22 Oct 2004; marketing authorisation withdrawn 18 Dec 2025.

2025, European Commission (EMA opinion).

On OnCo: Cinacalcet, Parathyroid carcinoma

Withdrawal: EU withdrawal: Lifileucel

2025-01-01T00:00:00Z

Marketing authorisation withdrawn in the European Union in 2025: MAA withdrawn 22 Jul 2025 after CHMP signalled a negative opinion (response rate, deaths, manufacturing).

2025, European Commission (EMA opinion).

On OnCo: Lifileucel, Melanoma, Non-small-cell lung cancer, Advanced melanoma

Law: European Health Data Space Regulation (EU) 2025/327

2025-01-01T00:00:00Z

A 2025 EU regulation that gives patients electronic access to their health records across the Union and creates national bodies that can grant researchers, regulators and companies permission to use anonymised or pseudonymised health data, phased in over the rest of the decade.

2025, European Union, regulation.

On OnCo: European Health Data Space Regulation (EU) 2025/327, GDPR and health data, Oncology EHR and real-world data platforms, Real-world evidence